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Archana Sidalaghatta Nagaraja, MS
Advisor: Anil K. Sood, MD
Abstract
Objectives: Catecholamine-mediated effects driven by elevated adrenergic
signaling are known to increase tumor growth and metastasis by direct effects on
tumor cells. However, knowledge of effects of adrenergic signaling on other cells
such as cancer-associated fibroblasts (CAFs) within the tumor microenvironment
is limited. We hypothesize that adrenergic signaling and norepinephrine can
accelerate the induction of CAF-phenotype to promote inflammation and
metastasis.
Methods: Ingenuity Pathway Analysis and NetWalker were used to assess gene
expression data from patients with known CESD (Center for Epidemiological
Studies-Depression)-score alongside microdissected CAFs from primary ovarian
cancer.

Tumor samples from mice exposed to daily restraint-stress or non-

stressed controls were assessed for alpha-smooth muscle actin (a-SMA)
expression. Normal fibroblasts (NoF 151) were treated with conditioned media
from non-treated and norepinephrine (NE) treated Skov3 and HeyA8 cells and
analyzed for induction of CAF-phenotype by a-SMA expression. Gene and
protein expression of cytokines and changes in migratory potential of fibroblasts
were assessed.
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Results: Among the significantly upregulated genes (fold-change >2) in patients
with known CESD-score, 34 genes overlapped with microdissected CAF data.
Among them are several networks involved in extracellular matrix (ECM) and
inflammatory response. Restraint stress was associated with significantly
increased levels of α -SMA, a marker for CAFs by both intensity and distribution
in Skov3, HeyA8 and ID8 tumors. These increases in α-SMA were abrogated
when mice were treated with broad beta-blocker propranolol during restraint
stress in HeyA8 and Skov3 model. Further bioinformatics analysis of these
datasets combined with gene array data from conditioned normal fibroblasts
showed collagens are the most important biological downstream effectors for the
adrenergic induced CAF phenotype. Consistent with the bioinformatics analyses,
there was increased collagen (assessed by Trichrome stain) in the tumors from
restraint-stress animals, and these were abrogated by propranolol treatment.
Upstream bioinformatics analysis of CAF mediators showed cancer-cell derived
INHBA (inhibin beta A, a member of the TGF-b family) can mediate the induction
of CAF-phenotype upon adrenergic stimulation. Silencing INHBA in tumor cells
decreased stress-induced tumor growth in Skov3 orthotropic model as well as
decreasing levels of CAFs and collagen in tumors.
Conclusion: Sustained adrenergic stimulation results in significant increases in
the CAF content in-vivo and accelerates conversion of normal fibroblasts to
CAFs in vitro (fold change-2 fold, p<0.05). Adrenergic-mediated changes in CAF
phenotype can increase production of pro-inflammatory cytokines and promote
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inflammation. This project provides a better understanding of the adrenergic
influences on the stroma within the tumor microenvironment.
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1 Introduction
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1.1

Chronic Stress

1.1.1 History of the “General Adaptation Response”
A stress response is an evolutionarily conserved and non-specific adaptation
mechanism that is triggered during distress or threats. Hans Selye pioneered the
work on stress in 1930s [1, 2]. In his early studies, he noticed common symptoms
such as loss-of appetite, muscle mass and anhedonia in patients who came to
hospitals with very diverse ailments such as burns, end-stage cancer, infectious
disease [2]. As a researcher who was studying the response of a new hormone
in rats, Han Selye discovered what he defined as the triad of responses:
enlarged adrenal glands, involuted lymphatic organs and severe bleeding in the
duodenum and stomach [3]. He attributed this to the ‘General Adaptation
Syndrome’ [4-6]. He further explained that this response consisted of 3 phases:
alarm reaction, resistance and exhaustion. In the first phase, which is the alarm
reaction, the body prepares to the threat by increasing levels of corticoids in the
bloodstream and the adrenal glands are depleted of lipids. As this phase
prolongs, the body enters the phase of resistance where there is an increased
supply of corticoids and lipids in the adrenal glands accompanied by
hemoconcentration and anabolism. The final stage, Hans Selye called the stage
of exhaustion where the body is can no longer fight the severe stress [7]. The
fundamental flaw with Selye’s experiments was that he hypothesized that stress
hormones run out after chronic episodes of stress, but subsequent studies on
stress responses showed that levels remain elevated and have several biological
implications.
16

1.1.2 Stress Response
Chronic stress is defined as a nonspecific response of the body to any long
standing demand. The ‘demands’ also known as stressors can be a physical or
an emotional exertion, but the biological manifestation will be the same [8].
Colloquially called ‘the fight-or-flight’ response, this refers to an acute response
that prepares the body to perceive and react to a threat. Such a response is both
necessary and indispensable to animals. Acute stress responses are what
enable a prey to run away form a predator, fight impending danger, and veer
away from an incoming car [9]. These examples manifest acute stress, which is
often short lived, transient and beneficial to the organism. In contrast, American
Psychological Association defines chronic stress in individuals as a “cascade of
negative emotions such as anxiety, anger and distress that also leads to
predictable biochemical, physiological, and behavioral changes”[8].
1.1.3 Biology of the stress response
The normal biochemical manifestation of a stress response is the same
irrespective of the source of stress. In response to a perceived threat, the
hypothalamus is activated. There are 2 arms to the stress response:
sympathomedullary pathway (SAM) or hypothalamic pituitary axis (HPA) that
leads to production of norepinephrine (NE) and cortisol respectively (figure 1). In
SAM, hypothalamic activation of the adrenal medulla results in the secretion of
epinephrine. Adrenal medulla is part of the autonomic nervous system and
chromaffin cells in the medulla are the primary source of catecholamines
epinephrine and norepinephrine in the body. At times of high sympathetic nerve
17

activation, the amount of norepinephrine entering the blood increases
dramatically. In HPA axis, hypothalamus activates the pituitary gland to produce
adrenocorticotropic hormone (ACTH). ACTH then stimulates the adrenal cortex
to produce corticosteroids such as cortisol that enters the bloodstream.

Figure 1: Stress Response. [10] (M.H. Antoni, S.K. Lutgendorf, S.W. Cole, F.S.
Dhabhar, S.E. Sephton, P.G. McDonald, M. Stefanek, A.K. Sood, The influence
of bio-behavioural factors on tumour biology: pathways and mechanisms, Nat
Rev Cancer, 6 (2006) 240-248.) Nature Reviews Cancer by NATURE
PUBLISHING GROUP. Reproduced with permission of NATURE PUBLISHING
GROUP in the format Republish in a thesis/dissertation via Copyright Clearance
Center.
In patients with cancer, both cortisol and norepinephrine levels are elevated with
different biological functions. Lutgendorf et al studied NE levels in ovarian cancer
18

patients in both blood plasma and tumors [11]. In 68 ovarian cancer patients,
tumor samples were collected and a pathologist confirmed for ovarian carcinoma
histology were confirmed. Tumor samples were obtained from 20 patients, and
plasma catecholamines were available for 53 patients (22 had ascites which is
the fluid accumulation in the peritoneal cavity commonly seen in ovarian cancer
patients). Patients were also assessed for biobehavioral profiles using CESD
(Center for Epidemiological Studies-Depression) scores and assessed as high
risk (score>=16) or low risk (score<15). Tumor samples and plasma were also
analyzed for NE levels using HPLC (high performance liquid chromatography).
Low risk patients showed minimal intra-tumor NE (all samples had less than
<0.1 pg/mg tissue assay), whereas tissues from high-risk patients showed
significantly greater NE concentrations with a significant increase in tumoral NE
with a mean = 19.5 ± 6.9 pg/mg tissue (figure 2). There were no significant
differences in plasma collected from the same patients 2 hours prior to resection
surgery. The authors of the study also point that the differences between tumor
and plasma levels of NE in the groups that catecholamines in peripheral
circulation are likely not responsible for the bulk of the intratumoral
catecholamine levels. Unpublished data in our lab has shown that chronic
adrenergic signaling can lead to neoinnervation driven by BDNF produced by
tumor cells. Peripheral nerves infiltrating the tumor can produce NE in the tumor,
and the low acidic pH of the tumor microenvironment also helps in increasing the
stability of NE within the tumor. Removal of the adrenal glands did not affect
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tumoral NE levels, indicating that systemic sources of NE do not drive tumoral
NE levels.

Figure 2: NE levels in ovarian tumors and circulating blood [11] (S.K. Lutgendorf,
K. DeGeest, L. Dahmoush, D. Farley, F. Penedo, D. Bender, M. Goodheart, T.E.
Buekers, L. Mendez, G. Krueger, L. Clevenger, D.M. Lubaroff, A.K. Sood, S.W.
Cole, Social isolation is associated with elevated tumor norepinephrine in ovarian
carcinoma patients, Brain Behav Immun, 25 (2011) 250-255.) Brain, behavior,
and immunity by Psychoneuroimmunology Research Society Reproduced with
permission of ACADEMIC PRESS in the format Thesis/Dissertation via Copyright
Clearance Center. Order License 4081680368687
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The primary reason to have a stress response was to be a protective response to
a perceived or imminent threat. At the end of the stressful experience, the body
gets back to normal by making biobehavioral or biochemical changes. This
process is commonly referred to as allostasis [12]. Bruce McEwen in his seminal
work on neurophysiology of stress, defined the term allostatic load as the impact
on the body as it forced to adapt to adverse situation, either psychological or
physical. He included that this can be attributed to either too much stress, or
inability of the stress hormones to turn off after the stressor has passed.
He explained there are 4 types of allostatic loads commonly seen (figure 3). In a
normal response, upon removal of stressor or after the perturbation has passed,
the body enters a recovery state and returns to normal (top panel). In abnormal
states, there could be a repeated hit or insufficient response. If a person is
subject to repeated stressors over a long period of time, the levels of cortisol can
stay elevated exacerbating the chronic effects of stress. In some individuals,
there may be a lack of adaptation that prevents allostasis (middle panels). In
some cases, there was an insufficient in the body’s ability to produce appropriate
responses. A prolonged response occurs when the signals indicated to stop the
stress response are not triggered in a timely manner (bottom panel left). In
general, catecholamines increase proinflammatory cytokines viaADRB2 receptor,
whereas glucocorticoids inhibit production. An inadequate response is generated
as shown (bottom panel right) when there is insufficient production of
glucocorticoids during a stress response. This results in prolonged elevated
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levels of proinflammatory cytokines (Nf-kappaB mediated cytokines) that cannot
be sufficiently inhibited by low levels of glucocorticoids.

22

Figure 3: Allostatic load [13] (B.S. McEwen, Allostasis and allostatic load:
implications for neuropsychopharmacology, Neuropsychopharmacology, 22
(2000) 108-124.) (Neuropsychopharmacology : official publication of the
23

American College of Neuropsychopharmacology by AMERICAN COLLEGE OF
NEUROPSYCHOPHARMACOLOGY Reproduced with permission of NATURE
PUBLISHING GROUP in the format Republish in a thesis/dissertation via
Copyright Clearance Center.
1.2

Acute v. chronic stress

In a typical stress response, as shown in figure 4, presence of a stressor is first
accompanied by increased production of catecholamines within first 30 min [14,
15]. The catecholaminergic spike provides the rapid response needed to counter
the stress by increasing via ADRB heart rate, alertness, reducing peripheral
vision. The glucocorticoids spike an hour after the initial stressor. The role of
glucocorticoids such as cortisol is to consolidate and terminate the stress
reactions, mobilize energy resources required for this purpose and facilitate
recovery. The long term genomic effect of GCs in the brain is to promote memory
storage in preparation for future events. Catecholamines and GCs are the most
important molecules produced in the stress response, and the following sections
describe common signaling mechanisms and effector molecules attributed to
both signaling pathways.
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Figure 4: Stress Response and Time [14] (E.J. Hermans, M.J.A.G. Henckens, M.
Joels, G. Fernandez, Dynamic adaptation of large-scale brain networks in
response to acute stressors, Trends Neurosci, 37 (2014) 304-314.) Trends in
neurosciences by ELSEVIER LTD.. Reproduced with permission of ELSEVIER
LTD. in the format Thesis/Dissertation via Copyright Clearance Center. Order
License Id: 4081680370430
1.2.1 Differences between catecholamines and corticosteroids
Catecholamines such as norepinephrine and corticosteroids such as cortisol
have different functions during the typical stress response. Sympathetic nervous
system is activated, accompanied by increased heart rate supplying blood to
muscles and other organs, increased mobilization of energy, decreased digestion
and increased breathing to maximize oxygen intake as the body prepares for the
threat. Cortisol stimulates gluconeogenesis thereby providing a steady source of
energy during the stress response. In addition, cortisol very potently decreases
immune function by blocking release of inflammatory molecules and also greatly
diminishes wound-healing capacity.

25

1.2.2 Adrenergic signaling
Catecholamine signaling in cells occurs via adrenergic receptors, which are all
intronless 7-transmembrane G-protein coupled receptors. Epinephrine and
norepinephrine signal via ADRA and ADRB receptors respectively. There are 5
alpha-adrenergic (ADRA) receptors ADRA1a, ADRA1b, ADRA2a, ADRA2b and
ADRA2c, and 3 beta-adrenergic receptors (ADRB) ADRB1, ADRB2 and ADRB3.
These receptors differ in the G-protein that it is associated with as well as their
tissue distribution. G proteins are guanosine-binding messengers downstream of
adrenergic receptors, and can be coupled to cAMP signaling (stimulatory (Gas),
inhibitor (Gi)) or coupled to phospholipase C (Gq). Alpha adrenergic receptors
are vasoconstrictive and play an important role in smooth muscle contraction
ADRA1 associated with Gq subunit that is vital for PLC signaling and smooth
muscle contraction. In heart, it activates a phosphatidylinositol-calcium second
messenger system and is important for ERK-signaling. ADRA2 subtypes are
coupled with Gi subunit that is the inhibitory and decreases both levels of cAMP
and neurotransmitter release. This in turn decreased smooth muscle contraction.
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Figure 5: Beta-adrenergic signaling [16] (S.W. Cole, A.K. Sood, Molecular
Pathways: Beta-Adrenergic Signaling in Cancer, Clin Cancer Res, 18 (2012)
1201-1206.) Clinical cancer research by American Association for Cancer
Research ; HighWire Press Reproduced with permission of AMERICAN
ASSOCIATION FOR CANCER RESEARCH in the format Thesis/Dissertation via
Copyright Clearance Center. Order License ID: 4081680372059
ADRBs are all primarily coupled to Gs or stimulatory G-protein subunit (figure 5).
Upon activation of receptor by norepinephrine, downstream signaling can
activate several pathways in several discreet cell types, and due to their clinical
importance, several agonists and antagonists for ADRBs have been identified
and studied extensively (Table 1). ADRB1 is coupled to Gas, ADRB2 to both Gas
and Gi and ADRB3 is coupled to Gi/nitric oxide pathway. Coupling to Gs
increases levels of cAMP and binds the regulatory subunit of PKA and the
activated catalytic subunit is released. PKA can phosphorylate serine and
threonine proteins on downstream effectors that have the PKA-specific motif
27

(Arg-Arg-any amino acid-Ser/Thr-hydrophobic amino acid) [16]. One of the most
important of this is phosphorylation of serine on CREB/ATF (cAMP Response
Element

Binding

Protein/Activating

Transcription

Factor).

Genome-wide

transcription analysis identified 10,447 full CREs and 740,390 half CREs sites in
the human genome with >4,000 sites on the genome where CREB proteins binds
[17]. Some of the targets of the transcription factors include important genes
related to transcription factor activation, cell metabolism, secretory factors and
cell cycle. To a smaller extent, downstream activation can also activate Nf-kB, an
important factor in promoting inflammation.
Type

ß1

Potency

Tissue

Characteristics

(antagonist)

Distribution

ISO > EPI =

Heart, lung, adrenal

Cardiovascular

NE (Practolol,

cortex, adipocyte

signalling, lipolysis

ISO > EPI >

WBC, NK cells, lung,

Bronchodilation, fight or

NE

bone marrow, appendix

flight response,

ICI 89,406)
ß2

ß3

(Butoxamine,

glycogenolysis, insulin

ICI 118,551)

secretion

ISO > EPI

Salivary gland, omentum,

(BRL-37344,

thyroid, gall bladder

Lipolysis, thermogenesis

Pindolol)
Table 1: Beta adrenergic receptor: functions, tissue distribution and chemical
modulators

28

1.2.3 Glucocorticoid signaling
Cortisol is the active glucocorticoid that is formed by corticosterone by HSD11b1
(11β-Hydroxysteroid dehydrogenase type 1) enzyme (figure 6) [18, 19].
Glucocorticoid receptor (GR) is the nuclear receptor with three domains an Nterminal transactivation domain, a DNA-binding domain and a C-terminal ligand
binding domain. The DNA-binding domain recognizes a DNA sequences called
as GR- responsive element. GR is inactive and in cytoplasm bound to various
factors but can be activated in the presence of cortisol. Glucocorticoids regulate
gene expression in three different ways: the first is to bind directly to DNA the
second one is to co-activate with other transcription factors bound to DNA and
third is by alteration of kinases. While association of GR to members of STAT
family of proteins enhance transcription, association of GR with Nf-KB decreased
their activity. Glucocorticoids are well studied in their modulation of inflammatory
pathways, specifically those related to Nf-kB. Reduced Nf-kB activity also results
in decreased transcription of IL-1b and osteocalcin. Glucocorticoids have potent
anti-inflammatory

actions

and

exacerbate

several

diseases

including

osteoporosis, glaucoma, cardiovascular and psychiatric diseases. The same antiinflammatory effects of GCs are also used to treat ailments driven by an
inflammatory response such as rheumatoid arthritis, eczema, asthma and
psoriasis [19-22]. Glucocorticoids were the first immunosuppressive drugs used
in

organ

transplant

patients

due

to

their

anti-inflammatory

and

immunosuppressive effects on several immune cells. GCs prevent dendritic cell
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maturation, suppress migration of neutrophils and have moderate activity on both
T and B cells [23-25].

Figure 6: Glucocorticoid Signaling [18] (R.H. Oakley, J.A. Cidlowski, The biology
of the glucocorticoid receptor: new signaling mechanisms in health and disease,
The Journal of allergy and clinical immunology, 132 (2013) 1033-1044.) The
Journal of Allergy and Clinical Immunology : In Practice by Elsevier. Reproduced
with permission of Elsevier in the format Thesis/Dissertation via Copyright
Clearance Center.
1.3

Effects of chronic stress on disease

Chronic psychological stress manifests in different ways in different people.
American Psychological Association defines stress as “uncomfortable emotional
experience accompanied by a predictable biochemical, physiological or
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behavioral changes” [26]. While acute stress is adaptive and can be beneficial
and important from an evolutionary perspective to prepare for an imminent threat,
chronic stress has no apparent benefits. Excessive chronic stress, which is
constant and persists over an extended period of time either due to repeated
stress or sudden events. Chronic stress can be physically and emotionally
debilitating, and increase risks of disease. Longitudinal and retrospective studies
studying the influence of psychological factors on human health and disease
study several cohorts of people. Glaser et al, showed that individual’s response
for pathogens was significantly different between long term caregivers compared
to non-caregivers due to altered immune response [27]. The same authors in
another study showed that longstanding marital stress was associated with
decreased immune function [28]. On the other hand, positive emotions and high
social support was associated with increased NK function [29].

In a study

involving 557 individuals, religious attendance was also associated with
decreased IL6 levels and consequently played a role in better survival [30]. In
SNS, hypersensitivity occurs during chronically stressful conditions. In preclinical
models, animals exposed to chronic and repetitive stressors are able to produce
and store higher amounts of catecholamines. These animals however do not
show catecholamine surge to the same extent as control animals when exposed
to the same stressor. However, presence of a new or novel stressor elicits an
exaggerated response indicative of hyper-responsiveness [31]. Some of the
common physiological responses to a stressor are summarized in Table 2 [32].
Elevated NE levels in tissue or plasma can directly affect cell types including
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cancer cells and the following sections summarize some of the most important
biological effects of catecholamines.
Table 2: Physiological response to stressor [32]
Oxygen and nutrients directed to the

Detoxification from toxic products

CNS and stressed body site(s)
Altered cardiovascular tone, increased Inhibition of growth and reproduction
blood pressure and heart rate
Increased respiratory rate

Inhibition of digestion-stimulation of
colonic motility

Increased gluconeogenesis and

Containment of the

lipolysis

inflammatory/immune response

1.3.1 Clinical Depression and CES-D score
Depression is one of clinical manifestations of chronic psychological stress. By
definition, depression or major depressive disorder (MDD) refers to a mental
condition characterized by lack of motivation and low mood that is persistent
across all situations for at least 2 weeks [33]. Among all mental disorders,
National Institute of Mental Health estimates MDD as the most common and
estimate about 6.7% of adult population had at least one major depressive
episode in 2015. National Comorbidity Survey was the first large scale
epidemiological study that looked at prevalence of MDD in Americans. The study
concluded that there was a 17% lifetime prevalence, and 6.7% of the population
showed symptoms of MDD in the past 28 days [34]. The same study also
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showed prevalence was at 21.3% in women and 12% in men. MDD also
accounts for the highest amount of years lost due to disability (YLD) among
mental disorders. YLDs are commonly used to define how ailments and diseases
affect workforce and its impact on economy. It is calculated by multiplying the
prevalence of a disorder (physical or mental) by the short- or long-term loss of
health associated with that disability (the disability weight) (figure 7).

Figure 7: Effect of MDD on YTD. National Institute of Mental Health, Retrieved
January

2017.

https://www.nimh.nih.gov/health/statistics/disability/us-ylds-

contributed-by-mental-and-behavioral-disorders.shtml
While certain genetic factors and biochemical factors might predispose a patient
to MDD, psychological stressors are the major cause. In the clinic, MDD is
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assessed by Center for Epidemiological Studies-Depression (CESD) screening
diagnosis. It was first published by Radloff in 1977 as a 20-point questionnaire
used to quantify depressive symptoms [35]. This is a self-report questionnaire
that is used broadly in epidemiological studies to assess clinical depression it has
shown good reproducibility and reliability across several populations [35]. This
reliability has been attributed to the nature of the questionnaire that focuses
primarily on psychological and cognitive effects of depression and not physical
parameters such as pain, loss of appetite etc. [35, 36]. A cutoff of 16 is
considered to a good indicator of risk of clinical depression with good specificity
and sensitivity. A correlation between cancer and high CESD have been shown
in other cancers such as ovarian, testicular, lung cancers [37-39].In a large scale
study comparing psychological evaluations between healthy and breast cancer
patients, there was a significant increase in CESD scores among cancer
patients. Not surprisingly, there was an increase in CESD score among patients
prior to initiating treatment and midway through their treatment (table 3) [40].
Mean CES-D scores of the patient group and healthy comparison group
Patient group

Healthy comparison group

F

Time 1

10.9 (sd = 8.9)

8.1 (sd = 7.0)

4.71

Time 2

12.8 (sd = 10.2)

7.8 (sd = 7.5)

11.72

Table 3: Differences in CESD Score among healthy and breast cancer patients
[40] (D. Hann, K. Winter, P. Jacobsen, Measurement of depressive symptoms in
cancer patients: Evaluation of the center for epidemiological studies depression
scale (Ces-d), Journal of Psychosomatic Research, 46 (1999) 437-443.) Journal
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of psychosomatic research by Leigh, Denis Reproduced with permission of
ELSEVIER INC. in the format Thesis/Dissertation via Copyright Clearance
Center.
In ovarian cancer, Huang et al studied ADRB status and depression symptoms
on survival [41]. For this study, the authors studied 237 patients from the Nurse
Health study. The anxiety and depressive symptoms were assessed using
Crown-Crisp Experiential

Index

(CCEI) and

ADRB2

status

assessed

by

immunohistochemistry. Tumors from 19% of patients stained positive for ADRB2
and these were also had significantly high levels of anxiety, depression
symptoms compared with those patients bearing ADRB negative tumors.
Dysregulation of the autonomic nervous system (ANS) is also associated with
depressed patients with coronary heart disease.

1.4

Effects of Stress on Disease

Chronic stress has adverse effects on a number of diseases and this is
summarized in the review below (figure 8). The following sections elaborate
further some of the most important effects of adrenergic signaling and NE.
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Figure 8: Effects of chronic stress on disease [42] (A.S. Nagaraja, N.C. Sadaoui,
P.L. Dorniak, S.K. Lutgendorf, A.K. Sood, SnapShot: Stress and Disease, Cell
Metab, 23 (2016) 388-388 e381.) Cell metabolism by ELSEVIER. Reproduced
with permission of ELSEVIER in the format Thesis/Dissertation via Copyright
Clearance Center.
Some of the earliest studies on effects of chronic stress were done to evaluate its
adverse

effects

on

cardiovascular disease.

Chronic

stress

effects

on
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cardiovascular tissue can occur in different ways (figure 9). Plasma levels of NE
(which is used as a biochemical indicator of adrenergic stimulation) is associated
with mortality and cardiovascular outcomes [43]. High levels are associated with
left ventricular dysfunction, high sympathetic activity in congestive heart failure
[44-46]. Stress-induced endothelial dysfunction can be attributed to reduced
vasodilation and accelerated atherosclerotic processes [47]. NE can also activate
the renin-angiotensin-aldosterone system (RAAS) and this pathway is activated
in patients with depressive symptoms [48-50]. Activation of aldosterone and
mineralocorticoid receptors can result in increased pro-inflammatory cytokine
production such as MCP1, MIF1a, and IL8 among others. NE and SNS activation
can increase atherosclerotic plaques, several mechanisms such as increased
cholesterol, increased macrophages, increased leukocytes, decreased vascular
smooth muscle cells and increased likelihood of plaque rupture [51-53]. Cardiac
tissue has an abundance of ADRB1 receptors, and resting heart rate is higher in
depressed patients irrespective of their hypertensive status [54].

Figure 9: Chronic stress and cardiovascular disease [55] A. Steptoe, M. Kivimaki,
Stress and cardiovascular disease, Nat Rev Cardiol, 9 (2012) 360-370.) (Nature
Reviews Cardiology by World Heart Federation Reproduced with permission of
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Nature Pub. Group in the format Republish in a thesis/dissertation via Copyright
Clearance Center.
Takatsubo cardiomyopathy commonly referred to as the broken-heart syndrome
is a temporary and reversible heart condition triggered by sudden severe or
emotional stress (such as death of a loved one, natural calamities, motor vehicle
accident etc) [56, 57]. This is foun most commonly in postmenopausal women,
and specific mechanisms are unknown. The sudden surge in catecholamine
signaling triggers left ventricular dysfunction that can then no longer contract
completely, resulting in the enlargement of the left ventricle to resemble a
Japanese pot.
1.4.1 Effects of chronic stress on immune system
Chronic stress-induced immune dysregulation can have significant deleterious
effects on health including blunted response to vaccination, slow and
compromised wound healing, reactivation of latent viruses such as Herpes
Simplex or Epstein–Barr virus (EBV), and increased risk other infectious
diseases [58-60] (figure 10). Several human studies have shown that
physiological stress impairs wound healing. Wound healing is a multiple step
processes initiated by an inflammatory response, which is sequentially followed
by proliferation (rebuilding tissue) and maturation (tissue remodeling phases).
The first phase of wound healing requires an inflammatory response to recruit
immune cells such as phagocytes and fibroblasts by producing chemokines and
cytokines and this is important because when this stage is impaired, healing is
disrupted [61, 62]. Proinflammatory cytokines such as IL6, TNF-a, IL1 are
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decreased in the wound site during psychological stress and this can delay
healing. Psychological stress, anxiety, depression have all been attributed to
decreased adaptive cell immunity involving both B-cells and T-cells thereby
increasing clinical risk of diseases [60, 63]. Psychological stress mediated
reduced cellular immunity can lead to increased recurrence of viral infections
including the herpes viruses, influenza, Hepatitis B and Epstein–Barr virus (EBV)
by reactivating latent viruses and altering immune responses to the virus [64-67].
Mechanistically, this is due to the shift in the cytokine profile from a Th1 toward a
Th2 profile that decreases cytokines important to mount a response against
viruses [27]. Chronic stress is also associated with reduced NK cell activity in
both human and animal models [68, 69].
Chronic psychological stress has been shown to be an aggravating factor in
inflammatory bowel disease (IBD). Catecholamines can change gut permeability
and bacteria adherence to mucosal surface [70]. Intestine is highly innervated
with sympathetic neurons and increased NE activated mast cells in the gut
mucosa driving inflammation and production of pro-inflammatory cytokines [71].
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Figure 10: Stress effects on Immune function [58] (J.P. Godbout, R. Glaser,
Stress-Induced Immune

Dysregulation:

Implications

for Wound

Healing,

Infectious Disease and Cancer, J Neuroimmune Pharm, 1 (2006) 421-427.)
Journal

of

neuroimmune

pharmacology

by

Society

on

NeuroImmune

Pharmacology Reproduced with permission of SPRINGER NEW YORK LLC in
the format Thesis/Dissertation via Copyright Clearance Center.
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1.4.2 Effects of chronic stress on viral biology
Norepinephrine and cortisol have several effects on viruses including accelerated
replication, reactivation of latent viruses and reduced response to therapeutics. In
a prospective study, a link was found between susceptibility to the common cold
and levels of psychological stress [72]. Cortisol is associated with enhanced
ability of HIV viruses to infect lymphocytes as well as immune suppression.
Norepinephrine is shown to activate HIV replication in vitro and reduced
response to antiviral therapy [73]. Increased HIV replication upon norepinephrine
treatment was due to activation of protein kinase A (PKA) downstream of
adrenergic receptors. This resulted in altered cytokine production by HIV-infected
PBMC, particularly decreased production of IL10 and IFN-gamma [74]. Herpes
simplex virus (HSV) can remain latent for many years in sensory and peripheral
ganglia and stress hormones such as norepinephrine can decrease latency of
disease. Mechanistically, this is because norepinephrine can decrease
production of interferon-gamma which activate macrophages that fight HSV
infection [75].
Unpublished data from our lab shows that NE can drive HPV-driven cervical
cancers by increasing tumor growth and metastasis. Treating tumor-bearing
animals with propranolol abrogated these effects.
1.4.3 Effects on nervous system
In patients with MDD studies looking at structural differences and functional MRI
(fMRI) in the brain suggest several changes in the activity of specific areas in the
brain. For example, there is hyperactivity in the ventromedial prefrontal cortex
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and lateral prefrontal cortex that modulates pain/aggression and assesses risk
respectively [76, 77] (figure 11). On the other hand, dorsolateral prefrontal cortex,
that is required for sustained memory processed, show decreased activity [78].
The amygdala is located deep in the brain's medial temporal lobe and is the
central component in the neural circuitry that processed emotions and pain.
Amygdala is heavily innervated by adrenergic system and NE levels increase
during stress [79]. Under emotional distress, amygdala is one of the main targets
of NE during pain modulation [79]. This has been shown to predispose
individuals to drug-seeking as well increased likelihood of drug relapse [80]. The
hippocampus is involved with memory and learning, and chronic stress and
stress hormones have been shown to impair both [81]. Clinical data shows that
patients exposed to severe stressful events (such as those diagnosed with
PTSD) show to a smaller hippocampal volume that can correlate to impaired
memory [82]. Long term potentiation refers to a neuronal process caused by
repeated and frequent activation of afferent fibers synapses that can strengthen
memory formation. Preclinical studies using rats have shown that chronic stress
can alter LTP in 2 regions of the hippocampus, CA3 and dentate gyrus [83]. In
preclinical models, stress impairs memory by altering ensuing synaptic plasticity
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and firing properties of hippocampal neurons [81]. In preclinical models, chronic
stress leads to depression-like behavior, including heightened fear learning in
presence of prey-scent, increased helplessness, fatigue and decreased
motivation for food and other rewards [84].

Figure 11: Regions exhibited significant between-group differences in regional
nodal parameters between control and patients with MDD [77] Figure as
originally published M. Ye, T.L. Yang, P. Qing, X. Lei, J. Qiu, G.Y. Liu, Changes
of Functional Brain Networks in Major Depressive Disorder: A Graph Theoretical
Analysis of Resting-State fMRI, PloS one, 10 (2015).
1.5

Chronic stress and cancer

1.5.1 Clinical studies
Psychological stress and clinical depression can affect outcomes such as
survival and relapse in several cancers such as lung, ovarian, breast, colon and
renal carcinomas [85-88]. Studies have also shown that clinical depression is
common among patients with melanoma, pancreatic, prostate, ovarian, breast, or
lung cancers [89-93]. Ovarian and breast cancers are the most widely studied
cancer for effects of depression, social support or other biobehavioral factors. In
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a study by Lutgendorf et al, of 68 ovarian cancer patients, low social support was
associated with elevated intratumoural NE level whereas there were no
differences in plasma levels [85, 86]. In another epidemiological study, Costanzo
et al. showed that in a cohort of 61 ovarian cancer patients, patients with low
social support also had higher levels of interleukin 6 (IL-6) in blood and ascites
[94]. A history of major depression is also associated with elevated plasma IL6
levels in breast cancer. Renal cell carcinoma patients with high CESD score
show a prominent pro-inflammatory signature in PBMC including high expression
of Cox2, IL6 and other markers [86].
Conversely, incidental usage of a beta-blocker is shown to have survival benefits
in several studies [95, 96] (figure 13). In one of the most comprehensive studies,
3561 patients with high-risk prostate cancer, of whom 1115 patients had used a
beta-blocker before and after diagnosis, use of a beta-blocker affected several
aspects of disease. It was significantly associated with a delayed onset of
disease, reduced risk of mortality from prostate cancer, a lower Gleason score
and a lower rate of distant metastasis [97]. Aspirin is a widely used NSAID that
was shown in this study to have an additive survival benefit when combined with
a beta-blocker. On a molecular levels, expression of ADRB2 in oral squamous
carcinoma cells was associated with greater tumor size, higher rate of lymph
node metastasis and advanced clinical stage in patients [96]. A retrospective
study done on patients with epithelial ovarian cancer showed that use of a betablocker increased both progression-free and overall survival when compared to
patients who had never used a beta-blocker. Several clinical studies support the
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beneficial role of beta-blockers in breast cancer as well. In a cohort of 466 breast
cancer patients, 43 patients who were on a non-specific or ADRB1-targeted betablocker (atenolol) for hypertension had significantly prolonged survival and lower
rates of metastasis as well as recurrence [98, 99]. In a contradictory study,
Barron et al. grouped breast cancer patients into those not on a beta-blocker,
those on atenolol (beta-1 selective) and those on propranolol (non-selective beta
blocker) [98]. Significant survival benefit was seen only among patients who were
on propranolol, and not on those on atenolol. Past therapy with propranolol was
also associated with lower tumor grade and lower incidence of metastasis than in
patients not on a beta-blocker. Use of a beta-blocker was associated with
reduced risk of death in patients with malignant melanoma. In a recent
retrospective study in non–small cell lung cancer, use of a beta-blocker (ADRB1
specific or non-selective) during radiation therapy was associated with
significantly better rates of overall survival, distant metastasis-free survival and
progression-free survival. In infantile haemangioma, propranolol is one of the
most promising options for therapy, as it decreases expression of VEGF, which is
vital in progression of this disease [100]. Propranolol is not approved by FDA for
pediatric cancers, but it has been used to treat cardiac ailments in children and is
documented to be well tolerated, with side effects that are seldom life
threatening. There are currently clinical trials underway to assess propranolol
(NCT01908972,

NCT01211080),

nadolol

(NCT01010308),

timolol

(NCT02731287) and other beta-blockers for treatment of hemangioma. Beta-

45

blocker usage is associated with decreased cancer-related mortality, using data
from the FDA Adverse Event Reporting System (figure 12) [101].

Figure 12: Effect of beta-blocker on cancer-related mortality [101]. (G.N. ArmaizPena, J.K. Allen, A. Cruz, R.L. Stone, A.M. Nick, Y.G. Lin, L.Y. Han, L.S.
Mangala, G.J. Villares, P. Vivas-Mejia, C. Rodriguez-Aguayo, A.S. Nagaraja,
K.M. Gharpure, Z. Wu, R.D. English, K.V. Soman, M.M. Shahzad, M. Zigler, M.T.
Deavers, A. Zien, T.G. Soldatos, D.B. Jackson, J.E. Wiktorowicz, M. TorresLugo, T. Young, K. De Geest, G.E. Gallick, M. Bar-Eli, G. Lopez-Berestein, S.W.
Cole, G.E. Lopez, S.K. Lutgendorf, A.K. Sood, Src activation by betaadrenoreceptors is a key switch for tumour metastasis, Nature communications,
4 (2013) 1403.) Nature communications by Nature Publishing Group.
Reproduced with permission of Nature Publishing Group in the format Republish
in a thesis/dissertation via Copyright Clearance Center.
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1.5.2 Preclinical models for chronic stress
Preclinical models of chronic stress are difficult to recapitulate when we try to
mimic all the psychological workings of chronic stress in humans. Biobehavioral
symptoms and signs of clinical depression such as suicidal thoughts, low selfesteem and mood swings are impossible to obtain in preclinical models. Hence,
scientists use predicted molecular and physiological responses to depression to
evaluate animal models (table 4) [102]. Restraint stress is one of the most widely
used models to mimic clinical depression for several reasons. This model
enables reliable assessment of stress-related biobehavioral and biochemical
changes in laboratory animals. The test is also easy to perform and has high
reproducibility. Restraint stress enables us to study both acute and chronic
stress, and produce a mental stress to animals that have low adaptability. In
addition, this test is also painless for the animals, and would not trigger other
pathways (such as hypothermia, pain) that might contribute to tumor growth.
Some of the other widely used preclinical models are summarized in the table
below.
Table 4: Animal models of chronic stress
Model
Tail Suspension

Advantages
Mice suspended from tail, time to Easy to perform
reach up measured

Wet bedding

Bedding of cage kept damp

Easy to perform

Learned

Exposure to uncontrollable

helplessness

unpredictable stressors Foot shock

and Easy to perform
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Maternal

Early stage stress model

deprivation
Forced swim test

Induces

anxiety

symptoms
Model for behavioral despair where Easy to perform
time to escape is measured

1.5.3 Effects on tumor initiation
Very little preclinical evidence shows a role for stress in driving tumor initiation.
Saul et al, used SKH1 which is a melanoma model susceptible to UV-induced
tumors to study effects of chronic stress on tumor initiation. Restraint stressed
animals had a shorter time to occurrence of the first tumor, which can be
interpreted as shortened latency to disease as true initiation. The stressed
animals also had high levels of proinflammatory cytokines and reduced T-helper
cells compared to controls [103]. In another model of melanoma, chemically
induced tumors using 7,12-dimethylbenz(a)anthracene (DMBA) alone (topical),
and

DMBA-12-O-tetradecanoylphorbol-13-acetate

(TPA)

after

chronic

unpredictable stress increased tumor incidence and tumor burden [104].
Innervation of peritumoral or intratumoral regions can produce catecholamines
and is increasingly shown to play roles in tumor progression in prostate,
pancreatic and ovarian cancers [105-108]. However, definite causation of tumors
owing to increased adrenergic stimulation is not well studied.
1.5.4 Direct effects on cancer cells
Some of the first studies looking at the molecular effects of norepinephrine on
cancer cells were done in ovarian cancer. Using restraint stress, Thaker showed
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that chronic restraint stress can lead to increased tumor growth and metastasis
[109]. Several cancer cells are positive for ADRB receptors. Activation of these
receptors activates transcription factors such as CREB, PKA and Nf-kB. Thaker
and Shahzad showed in independent studies that chronic stress increases levels
of VEGF and IL8 in an ADRB2 dependent manner thereby promoting
angiogenesis [109]. Sood et al also showed that NE and ADRB2 mediated
signaling can promote cell survival during anoikis that can further help
disseminated cells to metastasize effectively to distant organs [110]. ArmaizPena et al, showed that NE can potently induce metalloproteinases (such as
MMP2 and MMP9), Src, and FAK activation in cancer cells and contribute to
metastasis [101]. Hassan et al showed that NE could activate anti-apoptotic
signaling in a PKA-dependent manner and promote cell survival in a model of
prostate cancer [106]. In vitro studies in ovarian, colon, melanoma and
pancreatic cancer cell lines have shown NE can potently increase invasion and
migration of cells [111-114]. NE can also promote inflammation by increasing
PGE2 levels in an ADRB2-Nf-kB-PTGS2 axis in ovarian cancer [115]. NE can
also blunt effects of chemotherapy and anti-angiogenic therapy. Kang et al,
showed that NE can reduce effects of platinum and paclitaxel therapy in ovarian
cancer via NE-ADRB2-Jnk-DUSP1 pathway [116]. Preclinical models of lung and
colorectal cancers show that chronic stress can decrease the therapeutic benefit
of sunitinib by increasing VEGF, IL8 and these effects can be blocked by
propranolol. [117, 118]. In preclinical in vivo and in vitro studies, blocking NE
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using propranolol or specific beta-blockers can abrogate tumor growth,
metastasis or angiogenesis [107, 108].
1.5.5 Effects on stromal cells
There are an increasing number of studies that have shown that stromal factors
contribute significantly to all aspects of tumor progression including growth,
metastasis, immune suppression, angiogenesis, resisting cell death [119]. There
are several infiltrating immune cells such natural killer cells, tumor associated
macrophages, and T and B-lymphocytes. Tumor associated macrophages
produce VEGFA, an important factor in promoting angiogenesis, and can also
produce several proinflammatory cytokines. NK cells are cytotoxic lymphocytes
of the innate immune system that produce cytotoxic granules containing perforin
and various granzymes upon activation and cause perforations and apoptotic
death of tumor cells. Impaired NK cells or NK cell deficiency is associated with
increased incidence of cancer in preclinical models and human studies [120]. T
cells in tumors have been studied intensively over the past years and with
immunotherapy, is emerging as one of the main targets to treat various cancers.
Antibodies against checkpoint inhibitors such as CTLA4 or PD1 have shown
complete or partial response in renal cell carcinoma, head and neck cancer,
melanoma, lung cancer among others [121]. In several cancers, low cytotoxic Tcell infiltration (CTL) within tumors is associated with low survival. The
proinflammatory microenvironment is considered to one of the most important
impediments to T-cell infiltration [121]. Tumor associated endothelial cells have
weak intercellular connections resulting in a leaky vasculature that can contribute
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to metastasis. In addition they can a) produce several growth factors, b) engage
leukocytes and platelets and play a role in trafficking of immune cells and c)
produce factors such as PGE2, VEGF that impede T-cell infiltration into tumors
[122]. Some of the other cell types and their most important roles are
summarized in figure 13.

Figure 13: Stromal contributions to tumor progression.[119] (D. Hanahan, L.M.
Coussens, Accessories to the crime: functions of cells recruited to the tumor
microenvironment, Cancer Cell, 21 (2012) 309-322.) Cancer cell by CELL
PRESS. Reproduced with permission of CELL PRESS in the format
Thesis/Dissertation via Copyright Clearance Center.
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Effects of NE on stromal cells have not been as well studied as tumor cells
(figure 14). Armaiz-Pena et al showed that NE induced MCP1 production by
cancer cells can promote tumor-associated macrophages in ovarian cancer
[123].

Sloan et al, showed the NE-induced elevations in tumor-associated

macrophages increased breast cancer metastasis [124]. Ben-Eliyahu et al,
showed that in models of breast cancer and leukemia, NK cell activity was
suppressed during chronic stress and could attribute to increased tumor growth
[125, 126]. A study in brain cancer shows tumor endothelial cells are positive for
adrenergic receptors and can promote tubulogenesis and MMP9 secretion and
propranolol can block this effect [127, 128]. Infantile hemangioma is an
endothelial-derived tumor in which the first line of therapy is propranolol [129].

Figure 14: Effects of catecholamines on cancer and stromal components [88]
(S.W. Cole, A.S. Nagaraja, S.K. Lutgendorf, P.A. Green, A.K. Sood, Sympathetic
nervous system regulation of the tumour microenvironment, Nature reviews.
Cancer, 15 (2015) 563-572.) Nature Reviews Cancer by NATURE PUBLISHING
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GROUP. Reproduced with permission of NATURE PUBLISHING GROUP in the
format Republish in a thesis/dissertation via Copyright Clearance Center.
1.6

Cancer associated fibroblasts

A typical tumor contains endothelial cells, pericytes, immune cells such as
macrophages, T- and B-cells, cancer-associated fibroblasts, adipocytes and
other non-cellular components such as extracellular matrix and basement
membrane. Among them CAFs are usually the most abundant stromal cell in
tumors and play important roles in tumor progression. Once thought to be mere
bystanders, CAFs are currently studied extensively due to emerging studies that
show roles in chemoresistance, resistance to immunotherapy, metastasis and
invasion [130-132].
1.6.1 Definitions
CAFs can also be referred to as tumor-associated fibroblasts, activated
myofibroblasts or simply activated fibroblasts (figure 15) [133, 134]. Resident
fibroblasts in most normal tissue are resting or quiescent, however they become
‘activated’ during tissue injury and during presence of tumor cells. The cues that
trigger activation during wound healing is known but cues during tumor growth
are not studied well. Activated fibroblasts in both cases however show similar
characteristics in that they produce a number of cytokines, increase collagen
production, and show presence of certain markers of activated CAFs [134].
Functionally, these can have several growth-promoting effects on a tumor.
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Figure 15: Activation of fibroblasts [133] (R. Kalluri, The biology and function of
fibroblasts in cancer, Nat Rev Cancer, 16 (2016) 582-598.) Nature Reviews
Cancer by NATURE PUBLISHING GROUP. Reproduced with permission of
NATURE PUBLISHING GROUP in the format Republish in a thesis/dissertation
via Copyright Clearance Center.
1.6.2 Origin and markers
There is wide heterogeneity in CAFs and hence, there are several markers that
are taken together to identify them. Alpha-Smooth muscle actin (a-SMA) is the
most widely used CAF marker to identify tumoral fibroblasts and other markers
include

fibroblast-activated

protein

(FAP),

fibroblast-specific

protein-1

(FSP1/S100A4), neuron-glial antigen-2 (NG2) and PDGF β-receptor. Several of
these markers are common with other cells within tumors such as smooth
muscles (a-SMA), pericytes (NG2) and tumor cells (PDGFR-b). Morphologically
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similar CAFs may not stain positive for the same markers, and hence scientists
believe that there are a subset of CAFs in tumors [131, 133].
CAFs can also be derived from several sources, but primarily from 2 sources:
residual fibroblasts or recruitment of mesenchymal stem cells into tumors (figure
16). Several studies of colon, breast and lung cancers suggest that local
activation of fibroblasts contributes to CAFs in tumors [135]. Marini et al, used a
lethally irradiated RFP+ mice which were reconstituted with GFP+ bone marrow
to study local and bone-marrow derived stromal components in ovarian cancer
[136]. Using several markers for CAFs such as a-SMA, NG2, FSP and FAP, they
showed that a-SMA+ and NG2+ CAFs were derived from local tissue. FSP+ and
FAP+ cells co-stained with GFP indicating mesenchymal stem cell origin [136].
There is some evidence to show that epithelial cells exposed to reactive oxygen
species or MMPs during fibrosis can transdifferentiate into a CAF-like cell, which
can deposit ECM proteins and stains positive for a-SMA [137]. Preclinical studies
using GEM models with tagged lineages show that endothelial cells can also
show CAF-like phenotype in a process called EndMT (endothelial to
mesenchymal transformation) in melanoma [138].
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Figure 16: Origin of fibroblasts [132] (A. Ostman, M. Augsten, Cancer-associated
fibroblasts and tumor growth - bystanders turning into key players, Curr Opin
Genet Dev, 19 (2009) 67-73.) Current opinion in genetics & development by
ELSEVIER LTD.. Reproduced with permission of ELSEVIER LTD. in the format
Thesis/Dissertation via Copyright Clearance Center.
1.6.3 Functional roles in tumor microenvironment
Clinical studies have shown that higher levels of CAFs in colon, ovarian, lung,
and breast cancers are all associated with decreased survival [139, 140]. The
role of CAFs in driving tumor initiation and progression is multi-faceted (figure
17). When CAFs are co-incubated with premalignant cells, they can induce
tumors and promote malignancy [141]. CAFs can directly affect and increase
tumor growth. Activated fibroblasts produce a number of potent growth factor
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such as HGF, IL6, EGF and CTGF [130, 131, 139, 140, 142, 143]. These can
activate downstream signaling in tumor cells that promote both growth and
metastasis. CAF-derived prostaglandin E2 can also reduce NK cell activity in
tumors [144]. VEGF, TGFb, PDGFa derived from CAFs can stimulate endothelial
cell growth promoting angiogenesis [145-147]. CAFs also produce several ECM
proteins such as collagens that provide both signaling and scaffolding for tumor
metastasis. MMPs and TIMPs help breakdown ECM proteins as needed for
tumor growth. One of the biggest functions of CAFs is decreasing cell-mediated
immunity. CAFs produce several extracellular factors such as GM-CSF, IL6,
TGFb, CCL2, CCL5 that impede immune cell recruitment particularly T-cells.

Figure 17: Functions of CAFs [148] (R. Kalluri, The biology and function of
exosomes in cancer, J Clin Invest, 126 (2016) 1208-1215.) Nature Reviews
Cancer by NATURE PUBLISHING GROUP. Reproduced with permission of
NATURE PUBLISHING GROUP in the format Republish in a thesis/dissertation
via Copyright Clearance Center.
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1.7

Activin Signaling

Activins and inhibins are members of the TGF-b family of proteins. In normal
tissue, it is primarily expressed reproductive tissue such as gonads, uterus and
pituitary owing to its role in development of ovary, testis and follicle [149]. Inhibin,
beta A is also shown to play a role in driving glucose stimulated insulin secretion
in pancreatic beta-cells (figure 18) [149]. Inhibin, Beta A can drive SMAD
signaling via heteromeric complexes and activation of AVR2a and ACVR2b
receptors. Phosphorylation of SMADs 2/3 and SMAD4 complex leads to their
translocation to the nucleus. Here the proteins can bind to specific sequences in
the genome called SMAD binding element (SBE) and can drive transcription of
several genes [150].
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Figure 18: Inhibin, Beta A Signaling [150]. Figure as originally published in
Metpally RPR, Nasser S, Malenica I, Courtright A, Carlson E, Ghaffari L, Villa S,
Tembe W and Van Keuren-Jensen K (2013). Front. Genet. 4:20.
1.7.1 Inhibin, Beta A in cancer
Inhibin, Beta A (INHBA) is overexpressed in several cancers including prostate,
ovarian, pancreatic, breast, colon and other cancers. Inhibin, Beta A is
overexpressed in late-stage colon cancer patients compared to normal and early
stage disease [151]. In breast cancer patients, Inhibin, Beta A was
overexpressed invasive ductal carcinoma compared to normal breast tissue
[152]. Immunohistochemical staining also showed elevated p-SMAD2 and pSMAD3 in tumor samples compared to normal tissue. Recombinant Inhibin, Beta
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A increased anchorage-independent growth in breast cancer cell lines MCF7 and
MDA-MB-231 were used to study biological effects of Inhibin, Beta A [152]. In
vivo studies using Inhibin, Beta A-overexpressing cell line showed increased
tumor growth, metastasis and EMT. In prostate cancer, Inhibin, Beta A upregulates expression of AKR1C3 (Aldo-Keto Reductase Family 1 Member C3)
which is important for driving intratumoral levels of androgen. High levels of
Activin was also associated with worse survival in prostate cancer [153]. In
ovarian cancer, Inhibin, Beta A levels are higher in cancer compared to normal
and plays a role in promoting invasion and migration of cancer cells [154].
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2 Rationale and Significance
Several epideminiological and preclinical studies have shown that psychological
factors can have adverse effects on human health. These include increased
incidence of cardiovascular disease, inflammatory bowel disease, type 2
diabetes. Altered mental states such as depression or chronic stress, potently
activates the sympathetic nervous system to produce catecholamines either by
adrenal glands or local production by peripheral nerves. Recent evidence has
shown that cancer cells have receptors for catecholamines, and can promote
tumor growth, angiogenesis, inflammation, and macrophage infiltration. For this
project, we sought to find a link between high levels of tumoral catecholamines
and stromal components within ovarian tumors. I hypothesized that sustained
adrenergic signaling during chronic stress can accelerates induction of a CAFphenotype in ovarian tumors. My work demonstrates a) there is a prominent
stromal signature in patients with high depressive symptoms compared to those
with low depressive symptoms b) this is due to increased production of INHBA
(Inhibin, beta A) by cancer cells after NE stimulation in an ADRB2-CREB axis
and c) this results in activation of fibroblasts and these can increase collagen
levels in the tumor stroma. Together these data represent the first demonstration
that adrenergic signaling mediated Inhibin, beta A can drive CAF phenotype in
ovarian tumors. This work provides evidence that blocking Inhibin, beta A in
combination with beta-blockers may be a viable therapeutic target in chronically
stressed patients in order to block the deleterious effects of chronic stress on
patient outcome.
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3 Methods
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3.1

Cell lines

Skov3-ip1, A2780-ip2and HeyA8 ovarian cancer cell lines have been described
previously [101]. They were maintained in RPMI-1640 medium supplemented
with 15% fetal bovine serum and 0.1% gentamycin sulfate at 37°C. The ID8-ip1
murine ovarian cancer cell line was maintained in DMEM-high glucose medium
supplemented with 10% fetal bovine serum, 0.1% gentamycin, and 0.1% insulintransferrin sulfate [155]. NOF151 normal ovarian fibroblasts, whose derivation
has been described before [139, 156], were a kind gift from Dr. Jinsong Liu.
These cells were maintained in a 1:1 mixture of Medium 199 and MCDB 105
medium supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin,
and 5 µg epidermal growth factor. All cells were grown at 37°C in a humidified
chamber with 5% CO2.
For all in vitro experiments, cancer cells at 70% confluence were serum-starved
overnight before treatment. NE (10 μM; Sigma-Aldrich, St Louis, MO, USA) was
dissolved in sterile water just before it was added to the cells. Isoproterenol and
terbutaline (Sigma-Aldrich) were used at published concentrations [115, 116].
Propranolol and butoxamine were purchased from Tocris (Bristol, UK) and used
at published concentrations [115, 116]. Treatment with an antagonist, if pertinent,
began 1 h before NE was added to the cell culture medium. Treatment with
agonists was started at the same time as NE treatment. Genes were silenced by
using a reverse-transfection protocol with RNAimax and control siRNA
(sequence:

UUAUGCCGAUCGCGUCACA

Sigma-Aldrich),

specific

human

INHBA siRNA (sequence: CCAACAGGACCAGGACCAA Sigma-Aldrich), human
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ADRB2 siRNA (sequence: GCCATTACTTCACCTTTCA Sigma-Aldrich), human
ACVR2a siRNA (sequence: GCUCCAACCUCGAAGUAGA Sigma-Aldrich) and
human ACVR2b (CUCGACUUUGGGUUGGCCUU Sigma-Aldrich) according to
the manufacturer's recommendations. Briefly, 40 nm siRNA was mixed with
RNAimax transfecting agent and added to culture medium for 4 h. Fresh
complete medium was added and cells were allowed to grow. Silencing was
assessed at 48 h using quantitative reverse-transcriptase polymerase chain
reaction (qRT–PCR) analysis.
3.2

Chronic stress model

All animal experiments were approved by the Institutional Animal Care and Use
Committee at The University of Texas MD Anderson Cancer Center, where the
experiments were carried out. Experiments involving human cancer cell– and
murine cancer cell–derived mouse tumor models were performed in 8- to 12week-old female athymic nude and C57/B6 mice, respectively, obtained from
Taconic Farms (Hudson, NY, USA). Adrenalectomized mice were received from
Taconic Farms 3 days after surgery and were given an additional 10 days to
recover

before

restraint

stress

started.

Chronic

stress

was

induced

experimentally by using a restraint-stress procedure that has been previously
described [109]. In brief, mice were enclosed in a movement-restricted space for
2 h daily for the duration of the experiment (figure 19).
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Figure 19: Restraint system set up [109]. (P.H. Thaker, L.Y. Han, A.A. Kamat,
J.M. Arevalo, R. Takahashi, C. Lu, N.B. Jennings, G. Armaiz-Pena, J.A.
Bankson, M. Ravoori, W.M. Merritt, Y.G. Lin, L.S. Mangala, T.J. Kim, R.L.
Coleman, C.N. Landen, Y. Li, E. Felix, A.M. Sanguino, R.A. Newman, M. Lloyd,
D.M. Gershenson, V. Kundra, G. Lopez-Berestein, S.K. Lutgendorf, S.W. Cole,
A.K. Sood, Chronic stress promotes tumor growth and angiogenesis in a mouse
model of ovarian carcinoma, Nature medicine, 12 (2006) 939-944.) Nature
medicine by NATURE PUBLISHING GROUP. Reproduced with permission of
NATURE PUBLISHING GROUP in the format Republish in a thesis/dissertation
via Copyright Clearance Center.
Tumor cells were injected intraperitoneally into mice in all groups a week after
the stress procedure began (Skov3-ip1: 1 million cells/animal, HeyA8: 250,000
cells/animal, ID8-ip1: 2 million cells/animal). Mice were randomly assigned to
groups (n=10/group), and siRNA (3.5 µg in DOPC) treatment was started 5 days
after tumor cell injection and continued twice weekly for the duration of the
experiment. Mice were treated by intraperitoneal injection with propranolol or a
specific beta-blocker or adrenergic agonist daily for the duration of the
experiment. The animals were sacrificed by cervical dislocation when they
became moribund; the cadavers were examined for visible disease, and mouse
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weight, tumor weight, and number and distribution of nodules was noted by a
gynecologic oncologist blinded to the treatment groups.
3.3

siRNA delivery to tumors

Gene silencing was done using specific sequences incorporated into DOPC
nanoparticles as previously published [157, 158]. In short, siRNA is mixed with
DOPC in the presence of excess tertiary butanol at a ratio of 1:10 (w/w)
siRNA/DOPC. Tween20 is used as surfactant in the mixture, and the resulting
product is vortexed, frozen in acetone/dry ice bath and lyophilized. Particles are
hydrated with 0.9% saline before in vivo administration. Figure 20 shows delivery
of siRNA at the tumor site.

Figure 20: Tumors after delivery of siRNA in DOPC show siRNA in tumor, not
clustered near the vasculature (CD31 in green) [158]. (C.N. Landen, A. ChavezReyes, C. Bucana, R. Schmandt, M.T. Deavers, G. Lopez-Berestein, A.K. Sood,
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small
interfering RNA delivery, Cancer Res, 65 (2005) 6910-6918.) Cancer research :
the official organ of the American Association for Cancer Research, Inc. by
INTERNATIONAL

CANCER

RESEARCH

FOUNDATION

;

WILLIAM

H.
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DONNER

FOUNDATION

Reproduced

with

permission

of

AMERICAN

ASSOCIATION FOR CANCER RESEARCH in the format Thesis/Dissertation via
Copyright Clearance Center.
3.4

Immunofluorescence

Frozen slide-mounted tumor sections were fixed in acetone and washed in PBS.
Slides were incubated with the following primary antibodies overnight: α-SMA
(1:100, Abcam, Cambridge, MA, USA), FAP (1:100, R&D Systems, Minneapolis,
MN, USA), GFP (1:500, Abcam), and RFP (1:100, Abcam). AlexaFluor488 and
AlexaFluor594 fluorochromes (Jackson ImmunoResearch, West Grove, PA,
USA) conjugated to secondary antibodies were used for primary antibody
detection. Nuclei were identified by Hoechst stain (Invitrogen, Carlsbad, CA,
USA).
3.5

Immunohistochemistry

Both frozen and paraffin sections were used for immunohistochemical analyses.
Paraffin sections were heated for 20 min at 56°C and were deparaffinized in
xylene and dehydrated-rehydrated in decreasing grades of alcohol and PBS.
Antigen retrieval was performed in citrate buffer (pH 6.0) in the steamer for 30
min. Frozen sections were fixed in acetone and acetone-chloroform. After
endogenous peroxide blocking with hydrogen peroxide in methanol and three
washes with PBS, the slides were incubated with primary antibodies α-SMA
(1:100, Abcam), FAP (1:100, R&D Systems), or Inhibin, Beta A (1:100, Abcam)
overnight at 4°C. Sections were exposed to matching secondary antibodies
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(Jackson ImmunoResearch) for 1 h at room temperature and staining was
developed using 3,3'-diaminobenzidine. Nuclei were stained with hematoxylin.
3.6

Migration assay

Migration of NOF151 were measured in vitro. Inserts (8 μm; Millipore, Billerica,
MA, USA) were coated with 1% gelatin for migration assays. A total of 50,000
cells were placed in each upper well and allowed to move toward conditioned
medium in the lower chamber in the presence or absence of NE. Migration was
assessed 6 h after treatment by fixing the cells in Protocol Hema3 (Thermo
Fisher Scientific, Waltham, MA, USA). Cells were counted in randomly chosen
high-power fields, and cell counts are reported as average numbers of cells
migrated.
3.7

Collagen staining

Collagen distribution and density were assessed by using Masson trichrome
staining (Abcam) for both paraffin and frozen slides. Paraffin sections were
deparaffinized and dehydrated-rehydrated in alcohols and distilled water, and
frozen slides were dried at room temperature followed by fixation in formalin for
30 min. Slides were then fixed in preheated Bouin Solution (Sigma-Aldrich).
Slides were washed in tap water until the water ran clear, and Abcam’s staining
protocol was followed. Nuclei were stained with Weigert iron hematoxylin. Sirius
Red/Fast Green Collagen staining for collagens 1 and 3 was done by using a kit
(Chondrex, Redmond, WA, USA).
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3.8

qRT–PCR

Total RNA was extracted from cells by using the Zymo Research RNA isolation
kit with TRIzol reagent (Invitrogen) according to the manufacturer's standard
protocol. Complementary DNA was synthesized from 1 μg of total RNA using the
Verso cDNA Synthesis kit (Thermo Fisher Scientific) according to the supplier
protocol, using random hexamers and oligo-dT primers in a 3:1 ratio. Quantitative
PCR was performed using SYBR Green Master Mix on the 7500 Real-Time PCR
System (Applied Biosystems, Carlsbad, CA, USA) and standard protocols. The
primer sequences used are included in tables 5 and 6.
B-actin

AGCCTCGCCTTTGCCGA

CTGGTGCCTGGGGCG

ACTA2

CCAGAGCCATTGTCACACAC

CAGCCAAGCACTGTCAGG

INHBA

ATCTCGAAGTGCAGCGTCTT

GGAGGGCAGAAATGAATGAA

S100A4

TGTTGCTGTCCAAGTTGCTC

AACTAAAGGAGCTGCTGACC
C

FAP

TCAGTGTGAGTGCTCTCATTG

GCTGTGCTTGCCTTA

TAT

TTGGT

TCCACCTGGCTAAGGTTCTG

TGTCCTTCTACGTTCCCCTG

ACVR2a GAAAGCCCAGTTGCTTAACG

GAAAGCCCAGTTGCTTAACG

ACVR2b TGAGTACATGCTGCCCTTTG

TAATGGTGGGCCTCATCTTC

COL3A1

GATGGGGTCAAATGAAGGTG

GTGTGTTTCGTGCAACCATC

COL5A1

AGGATTTCCTGGACCAAAGG

TCTTGCCTTGGAAACCAGTC

COL5A2

CGGTGAAGAAGGCAAAAGAG

TTCTCCTTGAGCACCCTTTG

ADRB2
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COL11A

TCCTGGTGAAAAAGGACCAC

TTCTTTCCCAGGATGACCAG

ACAACCCTTCACCGTTCTTG

ATAGGGGTAAAGCTGGTCAG

1
CREB
pos1

G

CREB

GAGATTCTAAAGACCTGGGAA

neg

GG

CGACCCCAACCAACTTACAC

Table 5: Human Sequences (*ChIP primers)
B-actin

GCTACAGCTTCACCACCACA

TCTCCAGGGAGGAAGAGGAT

ACTA2

GTTCAGTGGTGCCTCTGTCA

ACTGGGACGACATGGAAAAG

S100A4

TTTGTGGAAGGTGGACACAA

CAGCACTTCCTCTCTCTTGG

FAP

CTTTGTGTTTCCTTCAGGTTTG

CTTTGGAGTTACCACCCTGG

ACVR2a

GGCGACATTGTTTTGCTACC

AGCCAACAACCTTGCTTCAC

ACVR2b

CTTTAAGCCCTTGCCTTTCC

TCACAGCCACAAAGTCGTTC

COL3A1

AGGATCTGTCCTTTGCGATG

TCTCCAAATGGGATCTCTGG

COL5A1

TGAACAGATGAAGCGACCAC

TATTCGCCATCTGGGAAGTC

COL5A2

TCCTCAGGGAATTGATGGAG

GCCATCTGAGCTGAAAAAGG

COL11A

TGGTCATCCTGGGAAAGAAG

ACCCTTTTCGCCTTTAGAGC

1
Table 6: Murine Sequences
3.9

Proteome profiler

NOF151 cells were exposed to serum-free medium, medium conditioned by
untreated cancer cells, or medium conditioned by NE-treated cancer cells. The
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conditioned media were spun down at 1200 rpm to remove cell debris. Total
protein from each culture was quantified according to Bradford protein assay,
and 250 μg of each protein sample was assayed in parallel using a Human
Cytokine Array kit (R&D Systems) according to the manufacturer’s protocol.
3.10

Inhibin, Beta A ELISA

The Inhibin, Beta A ELISA kit was obtained from MyBiosource (San Diego, CA,
USA). Supernatants from HeyA8 cells treated with NE or a specific beta-blocker,
and with control or INHBA siRNA, were collected and spun down to remove cell
debris. Supernatants were immediately stored at -80°C until use. The ELISA kit
was used per the manufacturer’s instructions. In short, a plate was incubated
with standards or 1:10 diluted supernatants for 2 h. The plate was then incubated
with biotin-labeled antibody for 1 h. After the plate was washed with PBS, it was
developed with colorimetric reagent and read at 540nm. Results are expressed
as pg protein/million cells.
3.11

Clinical samples

3.11.1 Renal cell carcinoma
Single cell suspension of patient tumor samples snap frozen at time of tissue
collection was obtained from the Department Behavioral Science at MD
Anderson Cancer Center. The protocols for handling and analyzing the
specimens were approved by the MD Anderson Institutional Review Board.
Patients provided written informed consent for the collection of specimens and
clinical data in accordance with the ethics guidelines of and with approval from
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the MD Anderson Institutional Review Board [86]. Patients were also completed
several psychosocial questionnaires. The Centers for Epidemiologic Studies Depression was used to assess depressive symptoms, with scores of 16 or
above classified as meeting screening criteria for depressive symptoms with
further evaluation recommended. 9 patients with stage 2 or 3 patients with 2
females and 2 males in low CESD score (CESD<10) and 3 males and 2 females
with high CESD score (CESD Score>20) were chosen for analysis.
3.11.2 Ovarian Cancer
Gene expression array results from GSE9116 were used to assess stromal
content in primary ovarian cancer patients with known depression scores. For
this dataset, tumor samples and psychosocial and behavioral data was obtained
from patients undergoing surgical resection of ovarian carcinoma. The protocols
were approved by Institutional Review Boards at University of Iowa, University of
Miami, and University of California Los Angeles. In short, 0.1 g of tumor was
processed for total RNA, and genome-wide transcription analyzed using
Affymetrix U133A high density oligonucleotide arrays.
3.11.3 Ovarian Cancer survival data using KMPlot
Primary ovarian cancer samples from The Cancer Genome Atlas (TCGA) was
used to survival graphs using an online tool[159]. In short, this tool uses gene
expression data (Affymetrix platform) from 522 patients to generate overall and
progression-free survival using the probe 210511_s_at for INHBA. The samples
were split by the median value and best cutoff was selected automatically. All
stages, histology, TP53 and debulking statuses were included in the analysis.
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3.12

Bioinformatics analysis

3.12.1 Netwalker
NetWalker was used to analyze whole tumor gene expression data from ovarian
cancer patients with known CES-D scores. For this scale, scores of 14 or less
are considered low stress and scores of 15 or 16 are considered high
stress. Unbiased networks of upregulated and downregulated genes were
developed by using Netwalker and Ingenuity Pathway Analysis. Analyses were
run considering the ratio (average of High stress/low stress). The network with
the highest scoring interactions throughout was identified, along with the
functions of the genes involved.
3.12.2 Oncomine
To identify genes that are significantly correlated with INHBA, we analyzed the
TCGA datasets for ovarian, colorectal, and breast cancers using Oncomine.
Significantly co-expressed genes from ovarian, breast, and colorectal cancers
were identified and tabulated.
3.12.3 RNA-Seq data
From the Level 3 (public) data from TCGA, including values from RNA-Seq
assays, we generated plots that included summary values for INHBA from “RNASeqV2” across all tumor types, including all samples for which these data were
available. The samples are ordered by tissue type.
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3.12.4 Statistical analyses
MS Excel or GraphPad Prism software was used to analyze data. Continuous
variables were compared by using the Student t-test or analysis of variance
(ANOVA), and the Mann-Whitney test was used to compare differences. We
determined that, using 2-way ANOVA, a sample size of 10 animals per group
would provide an effective size of 1.3 with 80% power at a significance of p=0.05.
We considered p<0.05 to be significant. All statistical analysis results were
expressed as mean ± standard error of the mean.
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4 Results
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4.1

Stromal signature in ovarian tumors from patients with chronic

adrenergic activation
My first goal was to identify potential pathways affected by adrenergic signaling.
We accomplished this by first comparing high-grade serous cancers (HGSC)
primary tumors from patients who had a high score on the CES-D from patients
who had a low CES-D score and low tumoral NE levels. CES-D is a widely used
self-report questionnaire to study depression in populations as this test has very
high internal consistency and adequate retest reliability. These data were
collected from a prospective cohort study (GEO GSE9116) [85] and we selected
for genes that were significantly upregulated in the tumors of patients with high
depressive symptoms (by at least 2-fold at the p<0.05 level). With the genes, we
then performed an unbiased analysis of gene expression networks using
NetWalker. I uncovered a strong signature indicative of a reactive stroma in
tumors from patients with high depressive symptoms (Figure 24a and Table 7). I
then compared the top 200 genes from these tumors with gene expression data
comparing microdissected CAFs and normal fibroblasts (GEO GSE40643), and
found 22 genes that were common to the high depression score group and the
CAFs, indicating that CAFs are indeed enriched during chronic adrenergic
signaling (Figure 21a and Table 8).
CAFs are associated with worse overall survival in ovarian cancer with
documented roles in inflammation, immune cell infiltration and metastasis. To
validate the biological relevance of these findings, I used beta adrenergic
receptor (ADRB) positive cell lines in orthotopic mouse models of both human
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(Skov3-ip1 and HeyA8) and murine (ID8-ip1) epithelial ovarian cancer. These
tumor models show increased tumor growth, metastasis and angiogenesis under
restraint stress. I induced chronic stress by using a well-characterized physicalrestraint system in which animals are physically confined in a small chamber for
2 hours every day for 21 days [101, 109]. In addition, restraint stress causes
sustained elevations of NE in tumors [109]. In tumors obtained at necropsy,
samples from mice exposed to chronic restraint stress had significantly greater
numbers of intratumoral cells positive for the CAF marker, alpha smooth muscle
actin (α-SMA), in all models (Skov3-ip1: 4.23-fold increase, p<0.05; HeyA8: 1.88fold increase, p<0.01; ID8-ip1 2.9-fold increase, p<0.05) (Figure 21b) [134].
Fibroblasts in tumors can also flank big vessels, and hence smooth muscle cells
can also stain positive for α-SMA, we also co-stained for CD31 and α-SMA. The
significantly higher α-SMA–positive signal in tumors from mice that underwent
chronic stress than in controls was independent of CD31-positive cells, indicating
that restraint stress induced an increase in the CAF phenotype (CD31independent a-SMA+ cells: 1.8-fold increase) (Figure 21c) [135, 160]. There was
a time-dependent CAF phenotype which was more pronounced in mice stressed
for 21 days than in those stressed for 7 days (Skov3-ip1: 2.1-fold increase,
p<0.05; ID8-ip1 2.2-fold increase, p<0.05) (Figure 24d). In addition to α-SMA,
other CAF markers such as fibroblast-activated protein (FAP), Platelet Derived
Growth Factor Receptor-α and S100A4 are commonly used. I also evaluated
another CAF marker, FAP and found a similar increase in its expression under
restraint stress in Skov3-ip1 model (Figure 22b). CAFs are an integral part of
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tumor microenvironment and CAFs were detected in primary as well as all
metastatic sites in these preclinical models of ovarian cancer. The CAF content
was increased by restraint stress compared to controls in the Skov3 model (2fold increase, p<0.05) in primary site and common places of ovarian cancer
metastasis such as omentum, peritoneum, and mesentery (Figure 22c). All of this
data shows adrenergic signaling can accelerate CAF induction within ovarian
cancer tumors in patient and preclinical models.
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Figure 21: Chronic stress accelerates induction of the cancer-associated
fibroblast (CAF) phenotype in ovarian carcinoma
(a) Results from NetWalker analysis to identify networks of upregulated genes in
ovarian cancer patients with high CES-D (i.e., depression) scores. (b) Expression
of alpha–smooth muscle actin (α-SMA, a CAF marker) in micrographs of
representative tumors from control and restraint-stressed mice in adrenergic
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receptor–positive Skov3-ip1, HeyA8, and ID8-ip1 models. (c) Expression of αSMA and CD31 (blood vessel marker) in micrographs of representative Skov3ip1 tumors from control and stressed mice. (d) Expression of α-SMA in
micrographs of representative tumors from mice subjected to short-term (7 days)
or long-term (21 days) stress. Scale bars, 100µM, n=5/group for all data.
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Figure 22: Restraint stress increases CAF content in primary as well as
metastatic sites.

(a) Venn diagram showing comparison of genes that are upregulated 2-fold in
tumor samples from ovarian cancer patients with a high depression (dep) score
compared to those with a low depression score and in microdissected cancerassociated fibroblasts (CAFs) compared to normal fibroblasts in primary ovarian
cancer. FC, fold-change. (b) Expression of CAF marker fibroblast activated
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protein (FAP) in micrographs of representative tumors from control and restraintstressed mice in the adrenergic-receptor positive Skov3-ip1 model. (c)
Expression of CAF marker alpha–smooth muscle actin (α-SMA) in micrographs
of representative normal tissues and matched metastatic tumors from the Skov3ip1 mouse model. Scale bars, 100µM, n=5/group for FAP data, n=3/group for
metastatic data.
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Annotation

Functional

Genes

ID

Annotation

GO:0031012

extracellular

COL5A3, COL5A1, COL1A2, LGALS1, COL1A1,

matrix

MMP11, PI3, SPARC, THBS1, COL8A1, COL8A2,
CTGF, TIMP2, TNC, DCN, COL6A1, COL3A1,
COL17A1, VWF, CTSD

GO:0005578

proteinaceous

COL5A3, COL5A1, COL1A2, LGALS1, COL1A1,

extracellular

MMP11, PI3, SPARC, COL8A1, COL8A2, CTGF,

matrix

TIMP2, TNC, DCN, COL6A1, COL3A1, COL17A1,
VWF

GO:0001568

blood vessel

COL5A1, COL1A2, COL1A1, ITGA5, THBS1,

development

ANPEP, COL8A1, COL8A2, C5AR1, CTGF,
TGFBR2, COL3A1, LYL1

GO:0001944

vasculature

COL5A1, COL1A2, COL1A1, ITGA5, THBS1,

development

ANPEP, COL8A1, COL8A2, C5AR1, CTGF,
TGFBR2, COL3A1, LYL1

GO:0044420

extracellular

COL5A3, COL5A1, COL1A2, COL1A1, SPARC,

matrix part

COL8A1, COL8A2, TIMP2, TNC, DCN, COL6A1,
COL3A1, COL17A1

GO:0051707

response to

CCL8, ACTA2, CD14, LBP, PLA2G2A, GPX3, SOD2,

other

CCL5, C5AR1, CXCL12, HCK, DCN, NFKBIA

organism
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GO:0031589

cell-substrate

COL5A3, LGALS1, ITGA11, COL1A1, ITGB5, ITGA3,

adhesion

THBS1, ITGB2, COL8A1, CTGF, COL3A1,
COL17A1, VWF

GO:0007596

blood

COL1A2, COL1A1, RAC2, ITGA5, ITGA3, SPARC,

coagulation

THBS1, ITGB2, TFPI, SLC16A3, PECAM1, COL3A1,
VWF

GO:0007599

hemostasis

COL1A2, COL1A1, RAC2, ITGA5, ITGA3, SPARC,
THBS1, ITGB2, TFPI, SLC16A3, PECAM1, COL3A1,
VWF

GO:0030247

GO:0032403

polysaccharid

COL5A3, COL5A1, SUSD2, CCL8, THBS1, CD14,

e binding

ABP1, CTGF, TGFBR2, NCAN, DCN

protein

COL5A1, ITGB5, ITGA5, THBS1, CTGF, TIMP2,

complex

HCLS1, COL3A1, VWF, NFKBIA, CTSB

binding
GO:0008544

GO:0043062

epidermis

COL5A3, COL5A1, COL1A2, COL1A1, LTB, EVPL,

development

KRT17, PPL, CTGF, COL3A1, COL17A1

extracellular

COL5A3, COL5A1, COL1A2, COL1A1, MYH11,

structure

COL8A2, CTGF, TNC, NCAN, COL3A1

organization
GO:0019838

GO:0005539

growth factor

COL5A1, COL1A2, COL1A1, IGFBP3, THBS1,

binding

IGFBP4, CTGF, TGFBR2, COL6A1, COL3A1

glycosaminogl

COL5A3, COL5A1, CCL8, THBS1, CD14, ABP1,

ycan binding

CTGF, TGFBR2, NCAN, DCN
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GO:0005581

collagen

COL5A3, COL5A1, COL1A2, COL1A1, COL8A1,
COL8A2, DCN, COL6A1, COL3A1, COL17A1

GO:0006954

GO:0007409

inflammatory

ALOX5AP, ALOX5, CCL8, THBS1, IGFBP4, CD14,

response

ITGB2, LBP, PLA2G2A, CCL5

axonogenesis

COL5A1, COL1A2, COL1A1, RAC2, ITGA5, MYH11,
UCHL1, NCAN, COL6A1, COL3A1

Table 7: Top networks upregulated in tumors from patients with high CES-D
scores compared to those with low CES-D scores, with corresponding involved
genes
Affymetrix

Symbol

Patient Samples Gene array for CAFs

202207_at

ARL4C

3.05

3.03

212077_at

CALD1

2.12

2.27

37892_at

COL11A1

4.47

5.674

201852_x_at

COL3A1

2.15

4.399

212489_at

COL5A1

2.09

3.809

221730_at

COL5A2

2.33

4.267

221541_at

CRISPLD2

3.11

3.083

201360_at

CST3

2.04

2.065

209101_at

CTGF

4.52

2.773

213274_s_at

CTSB

2.12

2.691

210764_s_at

CYR61

2.34

2.305

219454_at

EGFL6

2.71

3.673
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211719_x_at

FN1

2.28

2.777

211911_x_at

HLA-B

2.15

2.27

211990_at

HLA-DPA1

2.35

2.561

209312_x_at HLA-DRB1

2.62

2.445

211634_x_at

IGHM

2.12

2.326

216560_x_at

IGLC1

2.73

3.048

210511_s_at

INHBA

2.14

3.482

203417_at

MFAP2

2.08

2.52

209596_at

MXRA5

2.94

4.471

201058_s_at

MYL9

2.21

2.151

202620_s_at

PLOD2

2.14

2.562

210809_s_at

POSTN

2.88

4.933

218723_s_at

RGCC

2.03

2.767

203889_at

SCG5

4.31

2.185

212667_at

SPARC

2.07

2.984

203083_at

THBS2

2.09

2.568

201147_s_at

TIMP3

2.23

2.324

215034_s_at

TM4SF1

2.87

2.239

202241_at

TRIB1

2.43

2.374

203868_s_at

VCAM1

2.45

2.108

211571_s_at

VCAN

2.55

4.584

Table 8: Genes common to GSE9116 and GDS40643, arranged alphabetically
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4.2

Promotion of CAF phenotype by chronic adrenergic signaling

There are 3 ADRB receptors with distinct expression patterns in tissue and
varied biological functions. I first wanted to identify if this was due to direct effect
of NE signaling in fibroblasts and to do this, I used the A2780 cells that are
negative for all ADRB receptors. In this model, restraint stress has no effect on
tumor growth or metastasis but if there are direct effects of NE signaling on
fibroblasts, I hypothesized that there would be an increase in CAF content. There
was no significant difference in α-SMA expression between tumors from control
and restraint-stress groups (A2780: 1.1-fold change, p>0.05) (Figure 23a). The
increase in CAF content during restraint stress was only seen in ADRB+ cells,
indicating the important role of adrenergic signaling in tumor cells for driving the
stress-induced CAF phenotype.
Catecholamines such as norepinephrine, epinephrine can trigger signaling in
tumor and other cell types with ADRB and ADRA receptors respectively [88].
Compared to epinephrine, most tumor effects are driven by norepinephrine and
in patient tumors; depressive symptoms are associated with NE and not
epinephrine. To further assess the roles of norepinephrine signaling as the
primary catecholaminergic driver of the CAF phenotype under chronic stress, I
assessed the expression of α-SMA after chronic restraint stress in tumors from
adrenalectomized mice that had been injected with ID8-ip1 cells. In these
animals, the adrenal glands were surgically removed and tumor cells were
injected after the animal recovered. By adrenalectomy, we are eliminating the
primary source of circulating epinephrine and norepinephrine which are adrenal
87

glands, but preserving the primary source of norepinephrine (which is released
predominately

from

local

peripheral

nerves)

[161].

The

tumors

from

adrenalectomized mice had significant increases in α-SMA levels under restraint
stress (2.5- and 3.1-fold increases over controls in sham surgery and
adrenalectomy groups, respectively; p<0.05) (Figure 23b), implying a primary
role of NE. To further define the role of adrenergic receptors downstream of
adrenergic signaling, I used beta-blockers and agonists. Propranolol is an FDAapproved beta-blocker for cancer and cardiovascular ailments that works by
blocking all 3 ADRB receptors. Isoproterenol and terbutaline are broad and
ADRB2-specific beta-agonists which can be given systemically to activate ADRB
receptors. I first started by blocking all 3 ADRB using propranolol. I treated tumor
bearing mice with PBS or propranolol, a nonspecific beta-blocker that blocks all
downstream beta-adrenergic signaling in cells. Propranolol abrogated the stressmediated increases in α-SMA level in the HeyA8 model (PBS: 2.2-fold increases;
p<0.05, propranolol: 0.87-fold change, p>0.05) (Figure 23c) and reduced gene
expression of CAF markers in the Skov3-ip1 model (Figure 23c). Conversely,
treatment of tumor bearing mice with either isoproterenol (non-specific beta
agonist) or terbutaline (ADRB2-specific agonist) increased CAFs by 2.5 and 3.1fold, respectively in tumors (Figure 23d). Since agonists and beta-blockers are
not specific to tumor cells, and I wanted to see specifically the contribution of
adrenergic-signaling in tumor cells, we used siRNA incorporated into DOPC
nanoliposomes to silence ADRB2 in tumor cells. siRNA against human-specific
ADRB2 was incorporated into DOPC nanoliposomes and given at 5 ug per
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mouse biweekly by intraperitoneal injections. In the HeyA8 mouse model in
which ADRB2 was silenced by siRNA incorporated into nanoliposomes, stressmediated increases in α-SMA expression were abrogated (Figure 23e).
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Figure 23: Induction of the cancer-associated fibroblast (CAF) phenotype in
ovarian carcinoma is due to the indirect effects of adrenergic signaling.
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(a) Expression of CAF marker alpha–smooth muscle actin (α-SMA) in
micrographs of representative tumors from control and restraint-stressed mice in
the adrenergic-receptor (ADRB)–negative A2780 (orthotopic) model. (b)
Expression of α-SMA in micrographs of representative ID8 tumors from control
and stressed mice that underwent adrenalectomy (Adrenal.) or sham surgery. (c)
Expression of α-SMA in micrographs of representative HeyA8 tumors from
control and stressed mice treated with the nonspecific beta-blocker propranolol
or phosphate-buffered saline solution (PBS, controls). (d) ) Expression of α-SMA
in micrographs of representative HeyA8 tumors from control and stressed mice
treated with PBS (control), nonspecific beta-agonist isoproterenol, or ADRB2specific agonist terbutaline. € Expression of α-SMA in micrographs of
representative HeyA8 tumors from control and stressed mice treated with control
or ADRB2 siRNA loaded into nanoliposomal DOPC. Scale bars, 100µm,
n=5/group for all data.
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We also examined the consequences of tumor cell adrenergic stimulation for
fibroblast activation in vitro. We used NOF151, a normal fibroblast cell line that is
derived from normal ovary and has been previously characterized [139]. Similar
to fibroblasts in preclinical models, these cells have low expression of adrenergic
receptors and therefore do not respond to direct NE treatment, as indicated by
lack of increase in cAMP levels (Figures 24a and 24b). However NOF151 cells
exposed to either control medium conditioned by untreated cancer cells, or
medium conditioned by NE-treated cancer cells, we saw increased expression of
CAF markers ACTA2, FAP, and S100A4 RNA and α-SMA protein (Figures 24c
and 24d). Two characteristics of transformed fibroblasts in vitro are increased
production of pro-inflammatory cytokines and increased migration [141, 142].
Conditioned medium from NE-treated cancer cells increased expression of proinflammatory cytokines such as MCP1, CXCL1, MIF, GM-CSF, and G-CSF
(Figure 24e) and migratory potential (Figure 24f) in NOF151 cells. Taken
together, these results demonstrate that NE exposure induces tumor cells to
express soluble factors that enhance activation of normal fibroblasts.
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Figure 24: Conditioned media from NE-treated cancer cells accelerate
transformation of normal ovarian fibroblasts
(a) Expression of beta-adrenergic receptors (ADRB) in NOF151 normal
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fibroblasts relative to ADRB-positive Skov3-ip1 cells. (b) ELISA for cAMP in
NOF151 treated with norepinephrine (NE) for 15 or 30 min or not treated (NT).
(c) Expression of CAF marker alpha–smooth muscle actin ( 
-SMA) in NOF151
cells after exposure to medium conditioned by NE-treated Skov3-ip1 cells. (d)
Expression of CAF markers ACTA2, S100A4, and FAP in NOF151 cells after
exposure to medium conditioned by Skov3-ip1 cells treated with NE or NT. (e)
Immunoblot multiplex assay for pro-inflammatory cytokines in NOF151 cells
exposed to medium conditioned by NE-treated or NT Skov3-ip1 cells. (1: GCSF,
2: GM-CSF, 3:IL1a, 4: CCL2, 5: MIF, 6: CCL3, 7: PAI1) (f) In vitro migratory
potential of NOF151 cells toward serum-free medium (SFM), medium
conditioned by untreated Skov3-ip1 cells, or medium conditioned by NE-treated
SKov3-ip1 cells through 0.1% gelatin over 6 h was assessed by fixing and
counting the number of cells migrated per high-power field. Scale bars, 100µM.
Statistical significance was obtained using the 1-way ANOVA: *p < 0.05, **p <
0.01, ***p<0.001.
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Consistent with the adrenergic receptor specificity documented above in vivo,
NOF151 cells exposed in vitro to medium from isoproterenol- or terbutalinetreated cancer cells showed greater α-SMA induction than those exposed to
medium conditioned by non-treated cells (Figure 25a). Conditioned medium from
ADRB2-silenced cancer cells abrogated expression of CAF marker ACTA2 in

NOF151 cells (Figure 25b).
Figure 25: Restraint stress increases α-SMA in an ADRB2-dependent manner
(a) Expression of CAF markers ACTA2, S100A4, and FAP in NOF151 cells
exposed to serum-free medium (SFM) or to medium conditioned by Skov3-ip1
cells that were untreated (NT) or treated with norepinephrine (NE), nonspecific
beta-agonist isoproterenol (Iso), or ADRB2-specific agonist terbutaline (Terb). (b)
ACTA2 expression in NOF151 treated with ADRB2 or control siRNA and
m . S ta tis tica l

conditioned with NT or NE-treated Skov3-ip1 cells. Scale bar, 100
significance was obtained using the 1-way ANOVA: *p < 0.05, **p < 0.01,
***p<0.001.
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4.3

Stromal effects of chronic stress

I next wanted to study the biological consequences of fibroblast activation by
chronic stress. To obtain an unbiased approach, I used NetWalker for gene
expression analysis to identify upregulated networks in patient gene expression
array from GSE9116 (Figure 26a). From this analysis and the results shown in
Table 4, I identified that there was an increased collagen signature in tumors
during chronic stress. Collagens in ovarian tumors have been shown to drive
metastasis, impede immune cell infiltration and diminish chemotherapy efficacy.
To assess collagen content in tumors, histological staining is primarily used
including Masson’s Trichrome and Sirius. Masson Trichrome is used to identify
connective tissue from cells in histological samples. This is a chromogenic,
chemical based assay in which nuclei are stained black, connective tissue blue
and cytoplasm stains pink. Sirius is another chromogenic assay that
preferentially stains collagens 1 and 3. Masson trichrome staining and Sirius
staining of Skov3-ip1 and HeyA8 tumors confirmed elevated collagen deposition
after restraint stress in the in vivo mouse model (increase of 2.1-fold, p<0.05)
(Figure 26b). Stress-mediated collagen deposition in tumors was largely
abrogated by propranolol treatment in both models (1.64- and 1.01-fold increases
over controls in PBS- and propranolol-treated groups, respectively; p=0.05 for
PBS group) (Figure 26c).

Similarly, restraint stress–induced increases in

collagen were also abrogated by ADRB2 silencing, as shown by both trichrome
and Sirius staining (Figure 26d). Treating animals with the non-specific betaagonist or the ADRB2-specific agonist resulted in significant increases in tumoral
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collagen (1.81- and 1.75-fold increases for isoproterenol- and terbutaline-treated
groups, respectively, over PBS-treated controls; p<0.05) (Figure 26e).

Figure 26: Adrenergic signaling increases collagen deposition and extracellular
matrix formation in ovarian tumors.
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(a) An unbiased network of genes differentially upregulated in tumor samples
from high depression score and low depression score patients. (b) Expression of
collagen identified by Masson trichrome staining in micrographs of representative
Skov3-ip1 tumors from control and restraint-stressed mice. (c) Expression of
collagen in representative Skov3-ip1 tumors from control and stressed mice
treated with nonspecific beta-blocker propranolol or phosphate-buffered saline
solution (PBS, controls). (d) Expression of collagen identified by Masson
trichrome staining in micrographs of representative HeyA8 tumors from control
and stressed mice treated with control or ADRB2 siRNA. (e) Expression of
collagen identified by Masson trichrome staining in micrographs of representative
HeyA8 tumors from control and stressed mice treated with PBS (control),
nonspecific beta-agonist isoproterenol, or ADRB2-specific agonist terbutaline.
(Scale bars, 100µM, n=5/group for all data.
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Sirius stain is also a chromogenic stain more specific to collagens 1 and 3. Both
of these collagens were identified to be elevated in chronic adrenergic signaling.
Sirius staining showed collagens was significantly increased by 2-fold in both
HeyA8 and Skov3 tumors under chronic restraint stress (figure 27a). Similar to
Trichrome staining, Sirius stains showed adrenergic-mediated increases in
collagens 1 and 2 were abrogated during systemic propranolol treatment (Figure
27b). I also assessed expression levels of several collagens identified from the
patient datasets using murine-specific primers to identify only stromal-based
changes. Several genes involved in collagen synthesis were elevated in tumors
from mice exposed to restraint stress, and these increases were also abrogated
by propranolol (Figure 27c). Silencing ADRB2 in tumor cells using DOPC
nanoliposomes also decreased collagen 1 and 3 in tumors (Figure 27d). In vitro,
NOF151 normal fibroblasts exposed to medium conditioned by NE-treated
cancer cells showed similar elevations in the same collagen genes (Figure 27e).
However, NOF151 conditioned to ADRB2 silenced Skov3 cells did not show
these elevations in collagen genes (Figure 27f).
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Figure 27: Restraint stress increases collagen levels in tumors in an ADRB2
dependent manner
(a) Expression of collagen detected by Sirius staining in micrographs of
representative Skov3-ip1 and HeyA8 tumors from control and restraint-stressed
mice. (b) Expression of collagen detected by Sirius staining on micrographs of
representative HeyA8 tumors from control and stressed mice treated with
100

nonspecific beta-blocker propranolol or PBS. (c) Expression of collagen genes in
Skov3-ip1 tumors from control and stressed mice treated with nonspecific betablocker propranolol (Prop) or Saline. (d) Expression of collagen detected by
Sirius staining in micrographs of representative HeyA8 tumors from control and
stressed mice treated with control or ADRB2 siRNA. (e) Expression of collagen
genes in NOF151 cells exposed to medium conditioned by untreated (NT) or
norepinephrine (NE)-treated Skov3-ip1 cells. Scale bars, 100µM. (f) Expression
of collagen genes in NOF151 cells exposed to medium conditioned by untreated
(NT) or norepinephrine (NE) and ADRB2 silenced Skov3 cells. Scale bars,
100µM. Statistical significance was obtained using the 1-way ANOVA: *p < 0.05,
**p < 0.01 compared to controls, p<0.05 compared to stress or NE-treated cells.
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4.4

Induction of CAF phenotype by NE-mediated Inhibin, Beta A

production
My data demonstrates that cell contact between cancer cells and fibroblasts are
not required for the NE-induced CAF phenotype. I hypothesized that cytokines,
growth factors or other such extracellular factors were central to this
phenomenon. Using a gene array dataset of Skov3-ip1 and HeyA8 cells treated
with NE, we identified several potential genes that are induced by NE that could
be mediators of this effect [101]. I also wanted to identify potential upstream
regulators that are central to CAF activation in ovarian tumors. For this, I used
Ingenuity Pathway Analysis (IPA) on gene arrays of microdissected CAFs and
normal ovarian tissues to identify upstream regulators of CAFs [139]. Combining
the gene array and systems-based analyses, I identified IL6 (interleukin 6) and
INBHA (Inhibin, Beta A) as factors that could potentially drive CAF expression
(Figure 28a) [101]. IL6 is an important proinflammatory cytokine that is potently
induced upon NE treatment in ovarian cancer cells. In addition, elevated plasma
levels of IL6 are also associated with ovarian cancer patients who show
depressive symptoms. Inhibin, Beta A is also elevated in plasma of ovarian
cancer patients. However, there is no knowledge of NE driving Inhibin, Beta A
levels in cells. To identify which gene is more likely to be the mediator, I used
coexpression analysis of genes using Oncomine. Oncomine is a web-based
portal with publicly available datasets such as TCGA that enables users to do
survival, expression and other analysis. I used Oncomine to analyze coexpression of INHBA and IL6 with genes upregulated in ovarian cancer samples
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included in The Cancer Genome Atlas (TCGA). INHBA, but not IL6, was highly
correlated with stroma-related genes that were upregulated in both patient
datasets (Tables 9 and 10). Therefore, I focused primarily on INHBA for
subsequent experiments.
In the GEO data set GSE9116, I noted INHBA mRNA levels were increased 2.14
fold in tumors from patients with high depression scores (Figure 28b). In the in
vivo preclinical models, restraint stress significantly increased Inhibin, Beta A
levels in Skov3-ip1 and HeyA8 tumors (2.3- and 3.1-fold increases over nonstress controls, respectively, p<0.05) (Figure 28c). Treatment with propranolol
abrogated the increases in tumoral INHBA indicating that blocking betaadrenergic receptors can block this effect (Figure 28d).
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Figure 28: Induction of cancer-associated fibroblasts (CAF) in ovarian carcinoma
is mediated by Inhibin, Beta A downstream of norepinephrine.
(a) Schema used for Ingenuity Pathway Analysis (IPA) of three different ovarian
carcinoma cell lines to identify upstream regulators of CAF induction. (b)
Validation of Inhibin, Beta A levels in tumors from patients with high depression
scores and low depression scores; data were obtained from GEODATASET
GSE9116. (c) Expression of Inhibin, Beta A in micrographs of representative
Skov3-ip1 and HeyA8 tumors from control and restraint-stressed mice. (d)
Expression of Inhibin, Beta A in micrographs of representative HeyA8 tumors
from control and stressed mice treated with nonspecific beta-blocker propranolol
or phosphate-buffered saline solution (PBS, control). Scale bars, 100µM,
n=5/group for all data.
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Gene
Symbol

Reporter ID

Correlation

INHBA

210511_s_at

THBS2

203083_at

0.90183127

COL11A1

204320_at

0.8865286

COL11A1

37892_at

0.8865286

FAP

209955_s_at

0.8479447

CTSK

202450_s_at

0.8479447

VCAN

211571_s_at

0.8479447

SPARC

212667_at

0.8177246

AEBP1

201792_at

0.8177246

COL1A2

202403_s_at

0.8177246

COL6A3

201438_at

0.8177246

COL3A1

201852_x_at

0.8177246

COL5A1

212489_at

0.8177246

COL5A2

221730_at

0.8177246

MMP2

201069_at

0.81008625

SNAI2

213139_at

0.8011878

FBN1

202765_s_at

0.8011878

FN1

211719_x_at

0.7849791

COL10A1

217428_s_at

0.7731993

-

205941_s_at

0.7731993

CDH11

207172_s_at

0.7619725

1
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DCN

209335_at

0.7619725

LUM

201744_s_at

0.7619725

SERPINF1 202283_at

0.731467

CRISPLD2 221541_at

0.72007775

ASPN

219087_at

0.72007775

POSTN

210809_s_at

0.72007775

TMEM158

213338_at

0.7155617

OLFML2B

213125_at

0.7155617

ADAM12

213790_at

0.7155617

ADAM12

202952_s_at

0.7155617

NTM

222020_s_at

0.7155617

ECM1

209365_s_at

0.7155617

LRRC15

213909_at

0.7155617

MMP11

203876_s_at

0.7155617

COPZ2

219561_at

0.71121013

PCOLCE

202465_at

0.6899231

THBS1

201108_s_at

0.68605226

GLT8D2

221447_s_at

0.68131775

-

221019_s_at

0.68131775

MMP19

204575_s_at

0.67816544

COL6A1

212091_s_at

0.6591419

COL6A2

209156_s_at

0.6591419

ANGPTL2

213004_at

0.6519295
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ITGA5

201389_at

0.6519295

LOXL2

202998_s_at

0.6519295

RAB31

217762_s_at

0.6445346

PLAU

205479_s_at

0.6445346

VCAM1

203868_s_at

0.6445346

LPPR4

213496_at

0.6307415

ETV1

221911_at

0.6307415

COL16A1

204345_at

0.6217892

BGN

213905_x_at

0.6217892

C1QTNF3

220988_s_at

0.6091054

TIMP3

201147_s_at

0.6091054

-

214927_at

0.6091054

ITGBL1

205422_s_at

0.6091054

EPYC

206439_at

0.6091054

PRRX1

205991_s_at

0.60363436

EDNRA

216235_s_at

0.60363436

Table 9: Gene co-expression with INHBA in TCGA ovarian cancer samples
(highlighted probes common with Table 4)
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Gene
Symbol

Reporter ID

Correlation

IL6

205207_at

1

HBEGF

203821_at

0.533625

CH25H

206932_at

0.492976

THBD

203887_s_at

0.492976

NR4A3

209959_at

0.492976

GEM

204472_at

0.492976

RGS2

202388_at

0.492976

SLC2A14

216236_s_at

0.391042

SLC2A3

202497_x_at

0.391042

SGK1

201739_at

0.334213

PTGS2

204748_at

0.304811

NR4A2

204621_s_at

0.293695

DUSP2

204794_at

0.293695

BTG2

201236_s_at

0.293695

ZEB1

208078_s_at

0.293695

RHOB

212099_at

0.293695

JUN

201464_x_at

0.293695

IER2

202081_at

0.293695

JUNB

201473_at

0.293695

KLF6

208961_s_at

0.293695

GADD45B

207574_s_at

0.293695
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PPP1R15A 37028_at

0.293695

EGR2

205249_at

0.293695

CYR61

201289_at

0.293695

CTGF

209101_at

0.293695

ATF3

202672_s_at

0.293695

DUSP1

201044_x_at

0.293695

EGR3

206115_at

0.293695

NR4A1

202340_x_at

0.293695

FOSB

202768_at

0.293695

ZFP36

201531_at

0.293695

EGR1

201694_s_at

0.293695

FOS

209189_at

0.293695

CEBPD

203973_s_at

0.293695

EDN1

218995_s_at

0.293695

C10orf10

209182_s_at

0.293695

GADD45A

203725_at

0.293695

KLF10

202393_s_at

0.293695

BHLHE40

201169_s_at

0.293695

PLK3

204958_at

0.293695

DUSP5

209457_at

0.293695

LIF

205266_at

0.293695

MAFF

205193_at

0.293695

IER3

201631_s_at

0.293695
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C8orf4

218541_s_at

0.293695

Table 10: Gene co-expression with IL6 in TCGA ovarian cancer samples
(highlighted genes common with Table 4)
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In vitro, treatment of Skov3-ip1 cancer cells with NE significantly induced INHBA
expression, and pretreatment of HeyA8 cells with propranolol or ADRB2antagonist butoxamine abrogated this effect (Figures 29a and 29b). Silencing
ADRB2 using siRNA decreased INHBA expression in Skov3 cells after NE
treatment (Figure 29c). NE can activate several transcription factors but primarily
CREB1, Nf-kB and AP-1. Since Inhibin, Beta A gene was induced 3 hours after
NE treatment I decided to start by looking at transcriptional activation of INHBA.
TRANSFAC is a curated database for eukaryotic transcription factors, which
provides promoter region and binding sequences for all genes. Using this, I
identified CREB as potential transcription factor driving INHBA expression. Using
TRANSFAC, I identified and designed primers specific to the promoter regions of
INHBA where CREB1 binds. Chromatin immunoprecipitation analysis showed
that NE increased CREB binding to the INHBA promoter 4-fold compared to
normal IgG controls (Figure 29d). Silencing CREB1 using siRNA also reduced
NE-induced INHBA expression (Figure 29e). Conditioned medium from CREB1silenced Skov3-ip1 cells also failed to increase ACTA2 expression in NOF151
cells, demonstrating the importance of Inhibin, Beta A in driving the NE-mediated
CAF phenotype (Figure 29f).
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Figure 29: INHBA expression in tumor cells is mediated by ADRB2 and CREB
(a) Expression of INHBA in Skov3-ip1 cells after no treatment (NT) or treatment
with norepinephrine (NE) with or without propranolol or ADRB2-specific blocker
butoxamine. (b) Concentration of Inhibin, Beta A in HeyA8 cells after no
treatment or treatment with NE with or without propranolol, or butoxamine. (c)
Effect of silencing ADRB2 on INHBA expression in Skov3 cells not treated or
treated with NE. (d) Chromatin immunoprecipitation analysis for CREB binding to
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the INHBA promoter in Skov3-ip1 cells not treated or treated with NE. (e) Effect
of silencing CREB on INHBA expression in Skov3 cells not treated or treated with
NE.(f) Effect of medium conditioned by CREB1 siRNA– or control siRNA–treated
cells not treated or treated with NE on CAF marker ACTA2 expression in
NOF151 cells Scale bars, 100µM. Statistical significance was obtained using the
1-way ANOVA: *p < 0.05, **p < 0.01, ***p<0.001.
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I then wanted to check if silencing INHBA in cancer cells also prevent induction
of CAF-phenotype. I used several sequences for INHBA and validated
knockdown using ELISA and qRT-PCR. Conditioned medium from INHBAsilenced cancer cells failed to increase ACTA2 levels in NOF151 (Figure 30a30b). Functionally, NOF151 fibroblasts exposed to medium conditioned by
INHBA-silenced Skov3-ip1 cells also showed decreased levels of the same
collagens that were elevated in the patient tumor samples (Figure 30c and 30d).
Taken together, these results indicate that NE drives the CAF phenotype via an
ADRB2-CREB-INHBA axis.
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Figure 30: Conditioned media from INHBA-silenced tumor cells decrease CAFphenotype and collagens in NOF151
(a) Validation of multiple sequences of INHBA siRNA in HeyA8 cells not treated
(NT) or treated with norepinephrine (NE). (b) Concentration of Inhibin, Beta A in
HeyA8 cells after INHBA was silenced via siRNA sequence 2 and no treatment
or treatment with NE. (c) Effect of conditioned medium from INHBA siRNA– or
control siRNA–treated Skov3 cells on expression of CAF marker ACTA2 in
untreated or NE-treated NOF151 cells. (d) Effect of conditioned medium from
ADRB2 siRNA– or INHBA siRNA– NE-treated Skov3 cells on collagen
expression in NOF151 cells. Statistical significance was obtained using the 1-
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way ANOVA: *p < 0.05, **p < 0.01 compared to control, p<0.05 , ††p<0.01
compared to NE-treated cells.
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I then wanted to silence INHBA in vivo to study stromal changes more directly in
preclinical

models.

I

used

a

nanoliposomal

(1,2-dioleoyl-sn-glycero-3-

phosphatidylcholine [DOPC]) system to silence INHBA in the tumor cells in the
HeyA8 model. DOPC-based liposomes have been used to deliver siRNA and
microRNAs to tumor cells efficiently in multiple models of cancer. Animals are
treated with siRNA twice a week by IP injection. Restraint stress was induced
using the physical restraint system described in the methods. Silencing INHBA
decreased both tumor growth and metastasis (Figure 31a). Knockdown of INHBA
was validated by both RNA expression using human-specific sequences (Figure
31b). More importantly, silencing Inhibin, Beta A decreased restraint stress–
mediated increases in the CAF phenotype at both protein and mRNA levels
(Figure 31c and 31d). Silencing INHBA in HeyA8 tumor cells decreased collagen
deposition in vivo and also reduced levels of the collagens that were significantly
elevated in the patient tumor samples (Figure 31e and Figure 31f).
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Figure 31: Effects of silencing INHBA in cancer cells
(a) Effects of silencing INHBA in vivo on tumor weight and tumor in nodules in
orthotopic HeyA8 tumor-bearing mice subjected or not subjected (control) to daily
restraint stress and treated twice per week with either control siRNA or INHBA
siRNA. (b) Validation of knockdown of INHBA by qRT-PCR. (c) Expression of
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CAF

marker

alpha–smooth

muscle

actin

(α-SMA)

in

micrographs

of

representative HeyA8 tumors from control and stressed mice treated with control
or INHBA siRNA (d) Expression of ACTA2 after INHBA silencing. (e) Expression
of collagen identified by Masson trichrome staining in micrographs of
representative HeyA8 tumors from control and stressed mice treated with control
or INHBA siRNA. (f) Expression of collagens after INHBA silencing. Scale bars,
100µM, n=5/group for all data. Statistical significance was obtained using the 1way ANOVA: *p < 0.05, **p < 0.01 compared to siControl-no stress, †p<0.05,
††p<0.01 compared to siControl-Stress.
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I then focused on downstream signaling in NOF151 cells. Inhibin, Beta A
functions via ACVR2a or ACVR2b receptors and downstream activation of
Smad2/3 proteins. I started by staining the preclinical samples for both the
receptors. Tumor stroma was weakly positive for ACVR2a and positive for
ACVR2b (figure 32a). In vitro, I used NOF151 to silence both these receptors
and studied changes in CAF and collagen genes. Silencing ACVR2b, not
ACVR2a in NOF151 cells; abrogated changes in both ACTA2 and collagen
expression mediated by NE-conditioned media (figure 32b). Further downstream
of the receptors, SMAD proteins are activated by members of the TGFb pathway.
Exposure of fibroblasts to media conditioned by NE-treated cancer cells resulted
in a 3-fold increase in p-SMAD2 compared to media from non-treated cells
(figure 32c).
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Figure 32: Role of Activin receptor in driving collagens
(a) Expression of ACVR2a and ACVR2b in ovarian tumor stroma. (d) Effect of
NE-conditioned media after silencing ACVR2a and ACVR2b in NOF151 cells on
ACTA2 and collagen expression. (c) Effect of NE-conditioned media on
downstream SMAD2 activation in NOF151 cells.

Statistical significance was

obtained using the 1-way ANOVA: *p < 0.05, **p < 0.01 compared to siControl.
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To check if INHBA affected survival outcomes, I analyzed the TCGA dataset
using KMPlot. In 522 patients with high-grade serous ovarian cancer, primary
tumors were evaluated for INHBA (210511_s_at) expression levels. All stages,
TP53 status were included in the analysis with auto select of the best cutoff.
Elevated INHBA expression was associated with significantly shorter overall
survival in the TCGA ovarian cancer dataset (lower expression: 48.07 months,
high expression: 39.57 months) (Figure 33a). Elevated INHBA expression was
also associated with significantly progression-free survival in the TCGA ovarian
cancer dataset (lower expression: 20.63 months, high expression: 15.63 months)
(Figure 33a). Using Oncomine, I also assessed stage-wise expression of INHBA
in ovarian cancer and there was an increase in expression associated with
advanced stage (figure 33b).
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Figure 33: INHBA in ovarian cancer is associated with worse PFS and OS.
(a) Kaplan-Meier plots for overall survival (left) and progression-free survival
(right) in patients with ovarian cancer, based on expression level of INHBA. Data
were extracted from The Cancer Genome Atlas database. (b) Expression of
INHBA with stage (TCGA data).
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4.5

Adrenergic signaling–mediated CAFs modulate collagen in

breast and colorectal cancers
Clinical and preclinical data have shown that chronic stress can exacerbate
colorectal, breast, and prostate cancers in addition to ovarian cancer [88]. I
wanted to study which other tumor types also show induction of the CAF
phenotype during chronic adrenergic signaling. In both colon and breast cancers
greater numbers of CAFs are associated with shorter survival, increased
metastasis, and therapy resistance [130, 134, 162]. To determine whether our
findings apply to other cancer types, we examined both clinical data and in
vivo tumor samples from breast and colon cancer models. In mouse models
generated from ADRB-positive RKO colon cancer cells or GILM2 breast cancer
cells, α-SMA levels were significantly increased by restraint stress (2.2- and 3.4fold increases for RKO and GILM2, respectively; p<0.05) (Figure 34a). There
were concomitant increases in collagen in the tumors of mice subjected to
restraint stress (1.7- and 2.1-fold increases for RKO and GILM2, respectively;
p<0.05) (Figure 34b). Expression data from TCGA showed that INHBA levels are
higher in tumors than in normal tissue (Figure 34c). Most intriguingly, analysis of
genes that were co-expressed with INHBA in TCGA colorectal and ovarian
cancers revealed significant overlap with the prominent CAF phenotype observed
in ovarian cancer, and collagen patterns in these tumors were comparable to
those in ovarian cancer (Tables 11 and 12). To further show the importance of
chronic adrenergic signaling in promoting ECM- and CAF-related genes, we
analyzed an independent set of renal carcinoma samples from patients with
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known CES-D scores for collagens and CAF markers; the results show there is
higher levels of gene expression for collagens, INHBA and ACTA2 in patients
with higher depressive symptoms (Figure 34d).

125

Figure 34: Restraint stress induces cancer-associated fibroblasts (CAFs) in
colon, breast, and renal cancer models.
(a) Expression of CAF marker alpha–smooth muscle actin (α-SMA) in
micrographs of representative tumors from control and restraint-stressed mice in
adrenergic-receptor positive RKO (colon cancer) and GILM2 (breast cancer)
126

models. (b) Expression of collagen identified by Masson trichrome staining in
micrographs of representative RKO and GILM2 tumors from control and stressed
mice. (C) Pan-cancer INHBA expression from TCGA data. d)) Clinical validation
of adrenergic-mediated CAF-phenotype in renal cell carcinoma samples using
qRT-PCR p-values as indicated (total samples=9, 4 in CESD<4 and 5 in
CESD>21). Scale bars, 100µM, Means ± SEM, n=5/group for RKO data and
n=3/group for GILM2 data.
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Breast Cancer
INHBA

A_23_P122922

1

PPAPDC1A

A_24_P810284

0.847718

COL11A1

A_23_P11806

0.847718

KIF26B

A_23_P63541

0.804722

MMP11

A_23_P57417

0.79355

COL10A1

A_23_P214140

0.79355

GJB2

A_23_P407042

0.77325

FN1

A_24_P85539

0.756792

MMP13

A_23_P138931

0.713044

HSD17B6

A_23_P25030

0.704811

SPOCK1

A_24_P354689

0.675556

COL12A1

A_24_P291814

0.675556

CTHRC1

A_23_P111886

0.675556

COL3A1

A_24_P935491

0.675556

ASPN

NM_017680_2_2198 0.675556

AEBP1

A_23_P145918

0.675556

NOX4

A_23_P47147

0.675556

COL8A1

A_23_P69030

0.675556

COL1A2

A_24_P265274

0.675556

LOC651721

A_24_P282266

0.675556

WISP1

NKI_NM_003882

0.675556

LOC100128844 A_32_P141365

0.675556
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P4HA3

A_23_P127956

0.675556

TMEM90B

NM_024893_1_1555 0.675556

LRRC15

A_24_P827032

0.675556

CDH11

A_23_P152305

0.675556

POSTN

A_24_P347411

0.675556

ADAM12

A_23_P202327

0.675556

COL6A3

NM_004369_1_9684 0.675556

VCAN

A_23_P144959

0.675556

COL1A1

A_23_P207521

0.675556

COL5A2

A_23_P10391

0.675556

COL5A1

A_23_P158590

0.675556

THBS2

A_23_P253652

0.675556

FAP

A_23_P56746

0.675556

TNFSF4

A_23_P126836

0.655745

LOC401097

A_23_P305243

0.655745

CILP2

A_23_P108238

0.642901

CORIN

A_23_P81131

0.634304

TLL2

A_23_P404778

0.610464

ERMN

A_23_P102017

0.609356

PLAU

A_23_P24103

0.609356

SULF1

A_23_P43165

0.609356

KIAA1199

A_23_P324754

0.609356

GREM1

A_23_P432945

0.571732
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COMP

A_23_P90436

0.565048

PPEF1

A_23_P125505

0.543588

GRM8

A_32_P8221

0.543588

MATN3

NM_002381_2_2496 0.527919

C20orf103

A_23_P40294

0.527919

GRP

A_23_P101134

0.527919

ST6GAL2

A_32_P126157

0.527919

RGS4

A_23_P200737

0.510739

LOC285548

A_24_P892494

0.50405

NKX3-2

A_23_P386254

0.50405

Table 11: Gene co-expression with INHBA in TCGA breastl cancer samples
(highlighted genes common with ovarian cancer)
Colorectal Cancer
INHBA

A_23_P122922

1

COL11A1

NM_080629_1_6174 0.889562

ADAM12

NM_003474_2_4854 0.826843

NOX4

A_23_P47148

0.826843

CTHRC1

A_23_P111886

0.826843

FAP

A_23_P56746

0.826843

COL10A1

A_23_P214140

0.826843

COL5A2

A_32_P218731

0.811893

WISP1

NKI_NM_003882

0.809216
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PDPN

A_23_P201322

0.809216

COL8A1

A_23_P69030

0.786018

ITGA11

A_23_P206022

0.786018

P4HA3

A_23_P127956

0.786018

SULF1

A_23_P43165

0.786018

THBS2

A_23_P253651

0.786018

PPAPDC1A

A_24_P810284

0.786018

COL1A1

A_23_P207521

0.786018

COL12A1

A_24_P291810

0.786018

COL6A3

NM_004369_1_9860 0.786018

COL1A2

A_23_P255244

0.786018

SPARC

A_23_P7642

0.786018

ZNF469

A_23_P335080

0.786018

CDH11

A_23_P152305

0.786018

KAL1

A_23_P429948

0.754175

LOC651721

A_24_P282266

0.744667

HS3ST3A1

A_23_P66523

0.72371

POSTN

A_23_P205111

0.72371

LOX

NM_002317_3_1867

0.72371

TWIST1

A_23_P71067

0.715534

ST6GALNAC5 A_23_P33093

0.698786

LUM

A_32_P28664

0.698786

TMEM90B

A_24_P190504

0.698786
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FBN1

A_24_P152553

0.698786

ANTXR1

A_24_P131522

0.698786

NTM

A_23_P84060

0.698786

SPOCK1

A_23_P81598

0.698786

HTRA3

A_23_P395438

0.698786

TNFSF4

A_23_P126833

0.672474

MXRA5

A_24_P282355

0.662766

ADAMTS6

A_23_P213319

0.632247

KIF26B

A_23_P63541

0.632247

CNIH3

A_23_P384044

0.625946

SHISA2

A_32_P55236

0.625946

MMP11

A_23_P57417

0.625946

PPEF1

A_23_P125503

0.625946

MFAP2

A_23_P1027

0.625946

LRRC15

A_24_P827037

0.616798

HMCN1

A_23_P148991

0.616798

CRISPLD1

A_23_P59958

0.616798

COMP

A_23_P90430

0.616798

ITGBL1

A_23_P113777

0.616798

SFRP4

A_23_P215320

0.616798

KCNE4

A_23_P392574

0.604307

DIO2

A_23_P48736

0.581334

CLEC5A

A_23_P304356

0.550313
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SLN

A_23_P150343

0.550313

C5orf46

A_23_P19176

0.550313

FGF1

A_23_P213330

0.550313

OLR1

A_24_P124624

0.550313

SPP1

A_23_P7311

0.550313

MMP13

A_23_P138931

0.54776

ALPK2

A_23_P15876

0.54776

PRRX1

A_23_P502731

0.54776

FN1

NM_002026_1_7942 0.541192

DKK2

A_23_P155847

0.52731

GRP

A_23_P101134

0.52731

EDNRA

A_24_P217572

0.521915

Table 12: Gene co-expression with INHBA in TCGA colorectal cancer samples
(highlighted genes common with ovarian cancer)
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5 Summary and Future Directions
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5.1

Summary

A growing number of studies have shown a role of elevated adrenergic signaling
in driving tumor progression and adversely affecting survival. Epidemiological
studies, preclinical and in vitro studies in ovarian, lung, prostate, breast, renal
and colon cancers have shown norepinephrine can activate pro-survival and
metastatic networks on cancer cells that result in increased tumor growth and
decreased survival [88].
All the studies studying adrenergic influences focused on a particular aspect of
tumor progression, but in this study we start with an unbiased analysis to identify
novel pathways that are influenced by norepinephrine. Using clinical data from
patients with known biobehavioral profiles it enabled us to identify pathways that
included both cancer cells and stromal components.
Tumor microenvironment is a complex milieu with multiple host cells, including
macrophages, endothelial cells, infiltrating immune cells, and cancer associated
fibroblasts. Data showing effects on stroma is limited and was pursued further in
this study. In this dissertation, I focused on the effect and mechanism by which
catecholamine signaling in drives stromal changes in the microenvironment in
ovarian cancer (figure 35). Using gene expression data patients with known
depressive scores, I first identified a prominent association between depressive
symptoms and CAF phenotype. Cancer associated fibroblasts are important in
ovarian

cancer,

and

have

functions

in

driving

metastasis

and

immunosuppression [133]. Therefore studying the role of chronic stress in driving
CAFs in tumors can further explain some of the documented effects on tumor
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progression. Several genes that were elevated such as THBS2, ACTA2, and
SPARC are also established CAF markers. Elevated gene networks in patients
with high depressive symptoms include those associated with proteinaceous
extracellular matrix, collagens, and epidermis development primarily various
collagens. I then validated this CAF phenotype using both in vitro and in vivo
studies. Staining for a-SMA which is a prominent CAF marker, there are
significantly increased levels in Skov3, HeyA8 and ID8-VEGF in vivo models. In
vitro, normal ovarian fibroblasts that were exposed to NE-conditioned media from
cancer cells showed accelerated CAF induction. To identify the mechanism
leading to CAF-phenotype, I utilized both bioinformatic and molecular biology
approaches, and identified a novel mechanism of fibroblast activation triggered
by Inhibin, Beta A production by tumor cells in response to sustained adrenergic
stimulation. Inhibin, Beta A is a member of the TGF-b pathway that has direct
role on cancer cells in promoting tumor growth, but no data exists showing a role
in CAF phenotype. In TCGA clinical samples, INHBA was also highly correlated
with genes that were identified to be elevated in patients with high depressive
scores. Inhibin, Beta A production by cancer cells after NE treatment was
triggered by an ADRB2-CREB axis and silencing ADRB2 or CREB using siRNA
abrogated NE-induced Inhibin, Beta A production. Additionally, fibroblasts
exposed to conditioned media treated with from ADRB2 and CREB silenced cells
also did not show increases in CAF genes such as ACTA2, S100A4 and FAP.
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Figure 35: Summary
To determine the biological consequences of adrenergic-mediated CAF
phenotype, I focused on the extracellular matrix and collagen proteins. Using
histological Trichrome staining, I identified levels of several collagens such as
COL3A1, COL5A1, COL5A2 and COL11A1 are driven by downstream Inhibin,
Beta A-signaling in CAFs and were elevated during adrenergic signaling. When
animals were treated with beta-blockers, stress-related collagen increases in
tissue was eliminated. I also silenced Inhibin, Beta A in cancer cells using
liposomal nanoparticles containing siRNA, and this abrogated all collagen and
CAF changes in tumors.
To extend our findings to other cancers, we also studied colon and breast cancer
models using RKO and GILM2 in vivo models respectively. Chronic stress
significantly increased a-SMA, Inhibin, Beta A and collagen levels similar to
ovarian cancer. In addition, in both cases INHBA was also associated with high
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co-expression of collagen and CAF genes. Using an independent dataset of
renal cell carcinoma patients with known depression scores, there was a trend
towards increased ACTA2, INHBA and collagen genes associated with increased
CESD scores.
Work done in this project extends our understanding on how catecholamines can
affect the tumor microenvironment. For the first time, we have shown that INHBA
can be induced by NE stimulation in cancer cells, and this can induce a
prominent CAF phenotype in ovarian cancer. Association studies have shown
INHBA closely tracks with collagen genes in cancer, and we found similar results
using TCGA in ovarian, colon and breast cancers. However, our studies differ
from those published in that we show the association is casual and is driven by
INHBA inducing collagen genes. We provide evidence the silencing INHBA can
have profound effects on tumor stroma especially CAFs.
Although the principal effect is still on tumor stroma, the effect is still mediated by
norepinephrine acting on cancer cells. Blocking ADRB signaling in tumor cells
caused decreases in stromal content and CAF phenotype in several cancer
types. With increasing number of studies that are focusing on the role of chronic
stress in exacerbating diseases including cancer, we provide another motivation
to combine beta blockers with conventional therapy. Beta blockers are approved
by the FDA for heart disease (and infantile hemangioma) and are in clinical trials
for ovarian cancer. Propranolol is well tolerated and has very few side effects,
and provides another very targetable drug to block stromal changes.
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5.2

Future Directions

Chronic stress and NE-mediated ADRB2 and CREB signaling in cancer cells is
important for increasing angiogenesis, tumor invasion and inflammation. In
cardiac tissues, NE can promote fibrosis by increasing proliferation of primary
cardiac fibroblasts in a TGFb1-dependent pathway [163]. CREB driven Inhibin,
Beta A signaling in hippocampus is neuroprotective by reducing excitotoxic
neuronal damage [164]. Inhibin, Beta A is a member of the TGF-β pathway and
is overexpressed in prostate, ovarian, colorectal, and breast cancers [151, 165,
166]. Elevated serum and plasma levels of Inhibin, Beta A have been reported in
patients with metastatic ovarian, breast, and prostate cancers [151, 165, 166]. In
our study, silencing Inhibin, Beta A in tumor cells reduced the levels of
adrenergic stimulus induced CAFs and collagen significantly. Although coexpression of collagen genes with INHBA has been reported in some cancers,
the functional relationships have not been well understood [167].
Several studies have identified the direct role of NE in driving molecular changes
in tumor cells but influences on stroma have been limited to natural killer cells,
macrophage infiltration and angiogenesis [88]. Effects of adrenergic signaling on
CAFs and extracellular matrix provide a previously unrecognized dimension that
could have therapeutic implications. CAFs are the major part of tumor stroma
and provide tumor cells with vital cues for invasion by remodeling the
microenvironment through synthesis and deposition of collagens and producing
pro-inflammatory cytokines and other growth factors[133]. Targeting stroma can
lead to several clinical benefits including increased immune cell infiltration and
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decreased metastasis Collagens in the extracellular matrix can engage integrins
on tumor cells, impede T-cell infiltration and facilitate invasion and metastasis.
Importantly, collagens identified in our study (e.g., COL5A1, COL11A1 and
COL1A1) are also associated with increased metastasis and poor overall survival
in ovarian cancer [168].
5.3

Study Impact

Cancer diagnosis and treatment are extremely stressful events for patients and
families, and American Psychological Association also frequency reports that
chronic stress events in individuals are on the rise. Hence, studying the interplay
between stress hormones and their effects on tumor biology is becoming
increasingly important. To our knowledge, this is the first report that studies
adrenergic influences on tumor growth in a completely unbiased manner.
Although the role of chronic stress and psychological parameters are shown to
exacerbate

cancer

have

been

shown

in

several

cancers,

thoughtful

pharmacological and biobehavioral interventions to prevent this are few.
Biobehavorial interventions for cancer patients has been studied since 1970.
Some of the interventions that have been tried and proven to yield success
include regular therapy, relaxation training, social adjustment and also health
behaviour such as exercise, dietary modifications and strategies for symptoms
management (e.g., nausea, sleep deprivation). Biobehavioral interventions have
several limitations, including but not limited to high costs, treatment dropout, and
lower adherence to interventions. Hence, beta-blockers which are FDA-approved
with well tolerated side effects would be the ideal to treat chronic stress in cancer
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patients. In infantile hemangioma, beta blockers are the standard of care with
Beta blockers are currently being tested in clinical trials in combination with
chemotherapy in ovarian cancer. Understanding the various modes by which
catecholamines will affect tumor microenvironment will enable us to design novel
drug combinations with beta blockers.

Emerging data from molecular

underpinnings that drive NE-induced tumor growth can be harnessed further to
effectively combine therapeutic interventions (such as beta blockers) and
behavioural interventions with novel antagonists and inhibitors. There is data to
show that beta blockers can combine well with NSAIDs such as etodolac and
aspirin by blocking direct effects of NE and downstream inflammation signaling.
As studies continue to support the many molecular mechanisms that drive NEmediated tumor growth, several targeted therapies (such as bevacizumab or
immunotherapy) can be combined in large scale randomized studies to study
clinical benefits.
Inhibin, Beta A was identified in the study to be the most important extracellular
factor produced by cancer cells that can drive CAF phenotype in tumors. To our
knowledge, this is the first report to show that Inhibin, Beta A is necessary for
increased collagen levels in CAFs and may be an important biomarker for tumor
progression. This was not limited to ovarian cancer, but similar changes in NEinduced Inhibin, Beta A increased collagen levels in breast and colorectal
preclinical models. High depressive scores was also associated with high
expression of Inhibin, Beta A and collagens in renal cell carcinoma. Several
studies have focused on targeting Inhibin, Beta A to prevent cancer cachexia, but
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our results demonstrate important roles in modulating the tumor stroma [169-171]
that can be targeted to prevent potential tumor metastatic and increase T-cell
infiltration.
STM434, a humanized decoy receptor for activin receptor, is currently in a
clinical trial for treating patients with metastatic and chemotherapy resistant
ovarian cancer (NCT02262455). Single agent STM 434 showed an acceptable
safety profile in patients with advanced solid tumors and early evidence of clinical
activity. Beta-blockers are associated with survival benefit in several cancers and
our results suggest combining beta-blockers with novel targeting agents such as
Inhibin, Beta A decoy receptors in treatment regimens. Disruption of interactions
between cancer cells and stress hormones or cancer cells and fibroblasts may
improve outcomes of cancer patients. As the importance of Inhibin, Beta A and
collagens in driving cancers emerge, several therapies targeting them can be
combined with beta-blockers to improve patient survival in ovarian, colon, breast
and renal cell cancers.
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